Skip to main content
Psychedex
Sources
45
16 strong · 23 moderate · 6 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
103
72verified8partial23inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 15, 2026 · pipeline-v5
Values approved
92/92 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold0.125 mg0.125 mgmedium
Low0.25–0.5 mg0.25–0.5 mgmedium
Common0.5–1.5 mg0.5–1.5 mgmedium
Strong1.5–3 mg1.5–3 mgmedium
Heavy4+ mg4+ mgmedium
Editorial

Dose tiers based on clinical prescribing ranges (0.25–0.5 mg TID for anxiety, up to 4–10 mg/day for severe panic) and community harm reduction data. Threshold at 0.125 mg (half of lowest marketed tablet). Light range covers initial therapeutic doses. Common range covers standard therapeutic range. Strong and heavy ranges represent supratherapeutic/high-dose therapeutic use. Bioavailability 80–100% confirmed by Greenblatt 1993 and Smith et al. 1984.

Reasoning

Dose tiers based on clinical prescribing ranges (0.25–0.5 mg TID for anxiety, up to 4–10 mg/day for severe panic) and community harm reduction data. Threshold at 0.125 mg (half of lowest marketed tablet). Light range covers initial therapeutic doses. Common range covers standard therapeutic range. Strong and heavy ranges represent supratherapeutic/high-dose therapeutic use. Bioavailability 80–100% confirmed by Greenblatt 1993 and Smith et al. 1984.

Evidence basis: community_consensus_large

sublingualtrace

FieldPublishedAI ProposedConfidence
Threshold0.125 mg0.125 mglow
Low0.25–0.5 mg0.25–0.5 mglow
Common0.5–1.5 mg0.5–1.5 mglow
Strong1.5–3 mg1.5–3 mglow
Heavy4+ mg4+ mglow
Editorial

Sublingual efficacy confirmed by Marquez et al. 2011 for acute panic. Dose ranges assumed equivalent to oral given similar absorption expected from sublingual mucosa. No comparative bioavailability data published for sublingual vs oral alprazolam.

Reasoning

Sublingual efficacy confirmed by Marquez et al. 2011 for acute panic. Dose ranges assumed equivalent to oral given similar absorption expected from sublingual mucosa. No comparative bioavailability data published for sublingual vs oral alprazolam.

Evidence basis: published_case_series

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace15–30 minutes15–30 minuteshigh
Editorial

Onset derived from Tmax 0.7-1.8 hours (Greenblatt 1993) and Smith et al. 1984 PD data showing peak sedation at 30-60 min post-dose. First perceptible effects precede peak by 15-30 minutes.

Reasoning

Onset derived from Tmax 0.7-1.8 hours (Greenblatt 1993) and Smith et al. 1984 PD data showing peak sedation at 30-60 min post-dose. First perceptible effects precede peak by 15-30 minutes.

Evidence basis: controlled_human_study

Come uptrace15–30 minutes15–30 minuteshigh
Editorial

Come-up from first effects to approaching peak intensity spans approximately 15-30 minutes based on Tmax data (0.7-1.8h) and PD studies showing peak sedation at 30-60 min (Smith et al. 1984).

Reasoning

Come-up from first effects to approaching peak intensity spans approximately 15-30 minutes based on Tmax data (0.7-1.8h) and PD studies showing peak sedation at 30-60 min (Smith et al. 1984).

Evidence basis: controlled_human_study

Peaktrace1–2 hours1–2 hourshigh
Editorial

Peak duration derived from Smith et al. 1984: psychomotor impairment at 1.25-2.5h post-dose at 1 mg, with peak sedation at 30-60 min. Peak subjective intensity window approximately 1-2 hours centered around Tmax.

Reasoning

Peak duration derived from Smith et al. 1984: psychomotor impairment at 1.25-2.5h post-dose at 1 mg, with peak sedation at 30-60 min. Peak subjective intensity window approximately 1-2 hours centered around Tmax.

Evidence basis: controlled_human_study

Offsettrace2–4 hours2–4 hourshigh
Editorial

Offset (comedown) from peak to near-baseline. Smith et al. 1984: psychomotor performance returns to baseline at ~5h post-dose at 1 mg. After 1-2h peak ending at ~2-3h post-dose, offset spans approximately 2-4 hours.

Reasoning

Offset (comedown) from peak to near-baseline. Smith et al. 1984: psychomotor performance returns to baseline at ~5h post-dose at 1 mg. After 1-2h peak ending at ~2-3h post-dose, offset spans approximately 2-4 hours.

Evidence basis: controlled_human_study

Totaltrace4–8 hours4–8 hourshigh
Editorial

Total subjective experience duration. Based on PD data: onset at 15-30 min, peak at 0.7-1.8h, psychomotor return to baseline at ~5h for 1 mg (Smith et al. 1984). Higher doses extend duration. Total subjective window 4-8 hours depending on dose. Half-life 9-16h (Greenblatt 1993) exceeds subjective duration.

Reasoning

Total subjective experience duration. Based on PD data: onset at 15-30 min, peak at 0.7-1.8h, psychomotor return to baseline at ~5h for 1 mg (Smith et al. 1984). Higher doses extend duration. Total subjective window 4-8 hours depending on dose. Half-life 9-16h (Greenblatt 1993) exceeds subjective duration.

Evidence basis: controlled_human_study

After effectstrace6–24 hours6–24 hoursmedium
Editorial

Aftereffects extend well beyond subjective experience due to elimination half-life of 9-16 hours (Greenblatt 1993). Residual psychomotor impairment, cognitive slowing, and grogginess persist. Leufkens et al. 2007 documented driving impairment with alprazolam IR. Measurable impairment outlasts subjective drug awareness.

Reasoning

Aftereffects extend well beyond subjective experience due to elimination half-life of 9-16 hours (Greenblatt 1993). Residual psychomotor impairment, cognitive slowing, and grogginess persist. Leufkens et al. 2007 documented driving impairment with alprazolam IR. Measurable impairment outlasts subjective drug awareness.

Evidence basis: controlled_human_study

sublingual

FieldPublishedAI ProposedConfidence
Onsettrace5–20 minutes5–20 minutesmedium
Editorial

Sublingual onset faster than oral due to bypassing first-pass metabolism and direct mucosal absorption. Marquez et al. 2011 studied sublingual alprazolam for acute panic. Estimated from clinical use patterns; no published sublingual-specific Tmax data for alprazolam found.

Reasoning

Sublingual onset faster than oral due to bypassing first-pass metabolism and direct mucosal absorption. Marquez et al. 2011 studied sublingual alprazolam for acute panic. Estimated from clinical use patterns; no published sublingual-specific Tmax data for alprazolam found.

Evidence basis: controlled_human_study

Totaltrace4–8 hours4–8 hoursmedium
Editorial

Total duration expected to be similar to oral given same elimination half-life once absorbed. Faster onset may slightly shift timeline forward but total subjective experience duration comparable.

Reasoning

Total duration expected to be similar to oral given same elimination half-life once absorbed. Faster onset may slightly shift timeline forward but total subjective experience duration comparable.

Evidence basis: controlled_human_study

After effectstrace6–24 hours6–24 hoursmedium
Editorial

Aftereffects duration equivalent to oral route — same elimination half-life (9-16h) applies regardless of absorption route.

Reasoning

Aftereffects duration equivalent to oral route — same elimination half-life (9-16h) applies regardless of absorption route.

Evidence basis: controlled_human_study

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutelowlowhigh
Chronicmoderatemoderatehigh
Organs Affectedcns, respiratory, hepaticcns, respiratory, hepatichigh
Editorial

Acute toxicity classified as low: wide therapeutic index in isolation with no solo fatalities documented (Jann et al. 2014, INCHEM monograph), but polydrug combinations are critical/fatal. Chronic toxicity classified as moderate: persistent memory impairment that does not tolerate (Lucki et al. 1986), epidemiological dementia association (Verdoux et al. 2005), hippocampal effects (Santaya et al. 2026). No LD50 data available.

Reasoning

Acute toxicity classified as low: wide therapeutic index in isolation with no solo fatalities documented (Jann et al. 2014, INCHEM monograph), but polydrug combinations are critical/fatal. Chronic toxicity classified as moderate: persistent memory impairment that does not tolerate (Lucki et al. 1986), epidemiological dementia association (Verdoux et al. 2005), hippocampal effects (Santaya et al. 2026). No LD50 data available.

Evidence basis: systematic_review

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighhigh
Psychologicalhighhighhigh
Compulsive Redosingmoderatemoderatehigh
Dose Escalationmoderatemoderatehigh
Editorial

High physical and psychological dependence supported by multiple lines of evidence: precipitated withdrawal in squirrel monkeys after 9 days (Martin et al. 1995), >300% CRF mRNA increase on discontinuation (Skelton et al. 2004), one-third discontinuation failure rate (Rickels & Schweizer 1998), GABA-A receptor downregulation mechanism (Miller 1991). Compulsive redosing moderate — driven by negative reinforcement rather than euphoria. IR vs XR abuse liability difference confirmed (Mumford et al. 1995).

Reasoning

High physical and psychological dependence supported by multiple lines of evidence: precipitated withdrawal in squirrel monkeys after 9 days (Martin et al. 1995), >300% CRF mRNA increase on discontinuation (Skelton et al. 2004), one-third discontinuation failure rate (Rickels & Schweizer 1998), GABA-A receptor downregulation mechanism (Miller 1991). Compulsive redosing moderate — driven by negative reinforcement rather than euphoria. IR vs XR abuse liability difference confirmed (Mumford et al. 1995).

Evidence basis: controlled_human_study

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitysevereseverehigh
Symptomsanxiety rebound, tremor, insomnia, seizures, hyperarousal, irritability, nausea, vomiting, muscle tension, perceptual disturbancesanxiety rebound, tremor, insomnia, seizures, hyperarousal, irritability, nausea, vomiting, muscle tension, perceptual disturbanceshigh
FatalYesYeshigh
Medical SupervisionRequiredRequiredhigh
Editorial

Withdrawal onset within 6-24 hours reflecting the 9-16h half-life. Seizure risk makes withdrawal potentially life-threatening. CRF mRNA increases >300% within 24-48h (Skelton et al. 2004). One-third of patients unable to discontinue in 3-week taper (Rickels 1998). Medical supervision required due to seizure risk. Chlordiazepoxide substitution taper documented over 7-14 days (Closser 1994).

Reasoning

Withdrawal onset within 6-24 hours reflecting the 9-16h half-life. Seizure risk makes withdrawal potentially life-threatening. CRF mRNA increases >300% within 24-48h (Skelton et al. 2004). One-third of patients unable to discontinue in 3-week taper (Rickels 1998). Medical supervision required due to seizure risk. Chlordiazepoxide substitution taper documented over 7-14 days (Closser 1994).

Evidence basis: controlled_human_study

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidhigh
Half-life3 days3 dayshigh
Full Reset14 days14 dayshigh
Cross-tolerancesdiazepam, clonazepam, lorazepam, triazolam, zolpidem, zopiclone, alcohol, barbituratesdiazepam, clonazepam, lorazepam, triazolam, zolpidem, zopiclone, alcohol, barbiturateshigh
Editorial

Rapid tolerance buildup confirmed by multiple studies: Miller 1991 (GABA-A downregulation mechanism), Lucki et al. 1986 (selective tolerance to sedation but not memory), Duke et al. 2021 (subtype-specific contributions in rhesus monkeys). Cross-tolerance with all GABA-A PAMs is class-level pharmacology. Tolerance half-life/reset values are estimates — no specific reversal kinetics published for alprazolam.

Reasoning

Rapid tolerance buildup confirmed by multiple studies: Miller 1991 (GABA-A downregulation mechanism), Lucki et al. 1986 (selective tolerance to sedation but not memory), Duke et al. 2021 (subtype-specific contributions in rhesus monkeys). Cross-tolerance with all GABA-A PAMs is class-level pharmacology. Tolerance half-life/reset values are estimates — no specific reversal kinetics published for alprazolam.

Evidence basis: controlled_human_study

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
other known hypersensitivity to benzodiazepinestraceabsoluteabsolutehigh
Editorial

Standard pharmacological contraindication.

Reasoning

Standard pharmacological contraindication.

respiratory severe respiratory insufficiencytraceabsoluteabsolutehigh
Editorial

BZD class contraindication. INCHEM monograph lists respiratory depression as overdose complication. Risk magnified by polydrug combinations (Jann et al. 2014).

Reasoning

BZD class contraindication. INCHEM monograph lists respiratory depression as overdose complication. Risk magnified by polydrug combinations (Jann et al. 2014).

respiratory sleep apnea syndrometraceabsoluteabsolutehigh
Editorial

BZD class contraindication supported by prescribing information and clinical guidelines.

Reasoning

BZD class contraindication supported by prescribing information and clinical guidelines.

other acute narrow-angle glaucomatraceabsoluteabsolutehigh
Editorial

Standard BZD class contraindication listed in prescribing information.

Reasoning

Standard BZD class contraindication listed in prescribing information.

psychiatric post-traumatic stress disordertracerelativerelativehigh
Editorial

Cole & Kando 1993 reported PTSD worsening specifically with alprazolam, not other BZDs. This alprazolam-specific behavioral adverse event is documented in peer-reviewed literature.

Reasoning

Cole & Kando 1993 reported PTSD worsening specifically with alprazolam, not other BZDs. This alprazolam-specific behavioral adverse event is documented in peer-reviewed literature.

psychiatric borderline personality disordertracerelativerelativehigh
Editorial

Cole & Kando 1993 documented increased impulsive behavior with alprazolam in BPD patients.

Reasoning

Cole & Kando 1993 documented increased impulsive behavior with alprazolam in BPD patients.

psychiatric bipolar disordertracerelativerelativehigh
Editorial

Cole & Kando 1993 documented mania/hypomania induction more frequently with alprazolam than older BZDs.

Reasoning

Cole & Kando 1993 documented mania/hypomania induction more frequently with alprazolam than older BZDs.

hepatic severe hepatic impairmenttracerelativerelativehigh
Editorial

Greenblatt & Wright 1993 documented significantly reduced clearance in hepatic impairment. One case of cholestatic jaundice with focal hepatic necrosis reported (INCHEM).

Reasoning

Greenblatt & Wright 1993 documented significantly reduced clearance in hepatic impairment. One case of cholestatic jaundice with focal hepatic necrosis reported (INCHEM).

age elderlytracerelativerelativehigh
Editorial

Greenblatt & Wright 1993 confirmed significantly reduced clearance in healthy elderly. Age is an independent risk factor for benzodiazepine adverse effects.

Reasoning

Greenblatt & Wright 1993 confirmed significantly reduced clearance in healthy elderly. Age is an independent risk factor for benzodiazepine adverse effects.

pregnancy breastfeeding pregnancytracerelativerelativemedium
Editorial

Class-level benzodiazepine pregnancy risk. No alprazolam-specific teratogenicity RCT found in PubMed searches. Classified as relative rather than absolute due to absence of substance-specific data.

Reasoning

Class-level benzodiazepine pregnancy risk. No alprazolam-specific teratogenicity RCT found in PubMed searches. Classified as relative rather than absolute due to absence of substance-specific data.

other concurrent opioid usetraceabsoluteabsolutehigh
Editorial

Jann et al. 2014: 233.8% increase in alprazolam death rates 2003-2009, BZDs in 5-fold increase in overdose deaths. Vorce et al. 2010: fatal overdose at blood alprazolam 0.04 mg/L (below therapeutic range) combined with oxymorphone.

Reasoning

Jann et al. 2014: 233.8% increase in alprazolam death rates 2003-2009, BZDs in 5-fold increase in overdose deaths. Vorce et al. 2010: fatal overdose at blood alprazolam 0.04 mg/L (below therapeutic range) combined with oxymorphone.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Come uptrace900–1800 sec(i=0.30)900–1800 sec(i=0.30)high
Editorial

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Reasoning

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Peaktrace3600–7200 sec(i=1.00)3600–7200 sec(i=1.00)high
Editorial

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Reasoning

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Plateautrace7200–10800 sec(i=0.50)7200–10800 sec(i=0.50)high
Editorial

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Reasoning

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Resolutiontrace3600–7200 sec(i=0.20)3600–7200 sec(i=0.20)high
Editorial

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Reasoning

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Afterglowtrace14400–43200 sec(i=0.05)14400–43200 sec(i=0.05)high
Editorial

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Reasoning

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Onsettrace900–1800 sec(i=0.05)900–1800 sec(i=0.05)high
Editorial

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Reasoning

Timeline derived from published PK and PD data. Tmax 0.7-1.8 hours (Greenblatt 1993). Peak sedation at 30-60 minutes post-oral dose (Smith et al. 1984). Psychomotor impairment at 1.25-2.5h post-dose returning to baseline ~5h at 1 mg (Smith et al. 1984). Half-life 9-16 hours means residual effects persist well beyond subjective peak. Driving impairment confirmed by Leufkens et al. 2007.

Dose Tier Summaries

thresholdtrace
medium

At threshold doses (approximately 0.125 mg oral), effects are subtle and may be difficult to distinguish from placebo. A mild reduction in background anxiety becomes noticeable, with a slight sense of calm or emotional smoothing. Some individuals report faint muscle relaxation. Physically, effects are sub-perceptual for most people at this dose. No significant psychomotor impairment is expected. Sleep architecture may be minimally affected. Functional impairment is negligible at this level, though individual sensitivity varies — benzodiazepine-naive individuals may notice more pronounced effects than those with prior exposure.

Editorial

Threshold dose inferred from clinical dose-response data. The lowest marketed tablet is 0.25 mg; 0.125 mg represents a half-tablet threshold consistent with community reports. No controlled studies specifically characterize effects at this exact dose.

Reasoning

Threshold dose inferred from clinical dose-response data. The lowest marketed tablet is 0.25 mg; 0.125 mg represents a half-tablet threshold consistent with community reports. No controlled studies specifically characterize effects at this exact dose.

Evidence basis: community_consensus_large

lighttrace
high

At light doses (0.25–0.5 mg oral), anxiolysis becomes clearly perceptible. Subjective tension and worry diminish noticeably. Mild sedation emerges, with a sense of relaxation and reduced vigilance. Social inhibition may decrease slightly. At 0.5 mg, visual attention is impaired with a large effect size (d = 0.8), and attentional speed is reduced. Psychomotor performance begins to decline. Mild muscle relaxation is present. Some individuals experience subtle mood elevation. Driving ability is impaired at the upper end of this range. Sleep onset is facilitated, and the duration of commitment is approximately 4–6 hours of noticeable effects.

Editorial

The 0.5 mg dose has been characterized in controlled studies (Snyder et al. 2005, Chowdhury et al. 2016) with quantified cognitive effect sizes. Light dose range reflects the lower therapeutic dose range from clinical prescribing data.

Reasoning

The 0.5 mg dose has been characterized in controlled studies (Snyder et al. 2005, Chowdhury et al. 2016) with quantified cognitive effect sizes. Light dose range reflects the lower therapeutic dose range from clinical prescribing data.

Evidence basis: controlled_human_study

commontrace
high

At common doses, the full anxiolytic and sedative profile emerges. Anxiety is substantially reduced or eliminated. Emotional blunting becomes apparent — emotional responses are dampened, and distressing thoughts lose their urgency. Disinhibition increases, sometimes producing uncharacteristic social boldness or risk-taking. Cognitive slowing is noticeable: working memory and learning are impaired, and reaction times lengthen. Sedation is moderate and dose-dependent, with peak effects occurring 30-60 minutes after oral ingestion. Muscle relaxation is prominent. Psychomotor performance is impaired at 1.25-2.5 hours post-dose, returning toward baseline by approximately 5 hours at 1 mg. Driving ability is significantly compromised. Functional impairment is meaningful at this range. Complex tasks requiring sustained attention, memory encoding, or fine motor coordination should be avoided. Duration of impairment extends beyond subjective awareness of the drug's effects.

Editorial

Common dose range (0.5-1.5 mg) is the standard therapeutic range. Smith et al. 1984 documented psychomotor impairment timeline at 1 mg. Snyder et al. 2005 confirmed working memory and learning impairment at 1.0 mg. Leufkens et al. 2007 demonstrated driving impairment at 1 mg IR.

Reasoning

Common dose range (0.5-1.5 mg) is the standard therapeutic range. Smith et al. 1984 documented psychomotor impairment timeline at 1 mg. Snyder et al. 2005 confirmed working memory and learning impairment at 1.0 mg. Leufkens et al. 2007 demonstrated driving impairment at 1 mg IR.

Evidence basis: controlled_human_study

strongtrace
medium

At strong doses, sedation dominates the experience. Profound anxiolysis borders on emotional indifference. Cognitive impairment is marked: anterograde amnesia becomes likely, with partial or complete inability to form new memories during the period of peak drug effect. Disinhibition is pronounced, and judgment is significantly impaired. Euphoria may emerge, particularly in individuals with high baseline anxiety. Physically, sedation is heavy — most individuals experience overwhelming drowsiness. Psychomotor impairment is substantial: slurred speech (dysarthria), unsteady gait (ataxia), and delayed reflexes are common. Muscle relaxation is maximal. Driving or operating machinery is extremely dangerous. The risk of compulsive redosing increases at this range, particularly because amnesia may cause individuals to forget doses already taken. Duration of functional impairment extends well beyond the perceived drug effect.

Editorial

Strong dose range (1.5-3 mg) based on clinical prescribing data for panic disorder (therapeutic range extends to 4 mg/day) and community reports. Wright et al. 1997 documented increasing psychomotor impairment with each dose increment up to 8 mg. Amnesia risk at this range is well-established from benzodiazepine class data.

Reasoning

Strong dose range (1.5-3 mg) based on clinical prescribing data for panic disorder (therapeutic range extends to 4 mg/day) and community reports. Wright et al. 1997 documented increasing psychomotor impairment with each dose increment up to 8 mg. Amnesia risk at this range is well-established from benzodiazepine class data.

Evidence basis: controlled_human_study

heavytrace
medium

At heavy doses, deep sedation and near-complete cognitive incapacitation characterize the experience. Anterograde amnesia is virtually certain — entire hours may be lost from memory. Behavioral disinhibition can produce erratic, impulsive, or dangerous actions that the individual will not recall. Speech becomes severely slurred; coordination is grossly impaired. Physically, profound sedation may progress to stupor or loss of consciousness. Respiratory depression remains unlikely with alprazolam alone but becomes acutely dangerous if any other CNS depressant is present. Nausea is uncommon but aspiration risk increases if consciousness is impaired. This dose range carries the highest risk of adverse outcomes: injuries from falls or impaired judgment, compulsive redosing due to amnesia, and dangerous drug interactions. Recovery may take 12-24 hours. Residual cognitive impairment and grogginess persist well beyond the subjective return to baseline.

Editorial

Heavy dose range (>3 mg single dose) based on clinical overdose presentations and community reports. Wright et al. 1997 documented continued psychomotor impairment escalation up to 8 mg. INCHEM monograph describes overdose presentation (sedation, diplopia, dysarthria, ataxia). Wide therapeutic index in isolation confirmed by Jann et al. 2014.

Reasoning

Heavy dose range (>3 mg single dose) based on clinical overdose presentations and community reports. Wright et al. 1997 documented continued psychomotor impairment escalation up to 8 mg. INCHEM monograph describes overdose presentation (sedation, diplopia, dysarthria, ataxia). Wide therapeutic index in isolation confirmed by Jann et al. 2014.

Evidence basis: published_case_series

02

History

current version
published Jun 4, 2026AI-generated—
versions
2 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

16 strong · 23 moderate · 6 weak
  1. [1]
    weak
    Alprazolam - History and Legal Status
    Various · 2024
    linkno claims checked
  2. [2]
    moderate
    Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020.
    Diaz L, Eiden C, Jouanjus E, et al. · 2023 · Therapie
    doi.org/10.1016/j.therap.2023.02.002pubmed 369183171 claim checked1 partial
  3. [3]
    moderate
    Precipitated withdrawal in squirrel monkeys after repeated daily oral administration of alprazolam, diazepam, flunitrazepam or oxazepam.
    Martin JR, Moreau JL, Jenck F · 1995 · Psychopharmacology
    pubmed 76178192 claims checked2 partial
  4. [4]
    moderate
    Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics.
    Jann M, Kennedy WK, Lopez G · 2014 · Journal of pharmacy practice
    doi.org/10.1177/0897190013515001pubmed 244364375 claims checked4 verified1 inconclusive
  5. [5]
    weak
    An overdose death involving the insufflation of extended-release oxymorphone tablets.
    Vorce SP, Levine B, McDonough PC, Past MR · 2010 · Journal of analytical toxicology
    pubmed 218197983 claims checked2 verified1 inconclusive
  6. [6]
    strong
    Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.
    Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP · 1984 · Psychopharmacology
    pubmed 61520552 claims checked2 verified
  7. [7]
    moderate
    Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions.
    Sanna E, Pau D, Tuveri F, et al. · 1999 · Arzneimittel-Forschung
    pubmed 100839753 claims checked1 verified2 inconclusive
  8. [8]
    strong
    Alprazolam absorption kinetics affects abuse liability.
    Mumford GK, Evans SM, Fleishaker JC, Griffiths RR · 1995 · Clinical pharmacology and therapeutics
    pubmed 76979544 claims checked1 verified3 inconclusive
  9. [9]
    strong
    Clinical pharmacokinetics of alprazolam. Therapeutic implications.
    Greenblatt DJ, Wright CE · 1993 · Clinical pharmacokinetics
    pubmed 851364918 claims checked8 verified10 inconclusive
  10. [10]
    moderate
    Rationalizing the binding and alpha subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies.
    Golani LK, Yeunus Mian M, Ahmed T, et al. · 2022 · Bioorganic & medicinal chemistry letters
    doi.org/10.1016/j.bmcl.2022.128637pubmed 352188825 claims checked3 verified2 inconclusive
  11. [11]
    moderate
    Chronic benzodiazepine administration: from the patient to the gene.
    Miller LG · 1991 · Journal of clinical pharmacology
    pubmed 16525963 claims checked2 verified1 partial
  12. [12]
    moderate
    Chronic use of benzodiazepines and psychomotor and cognitive test performance.
    Lucki I, Rickels K, Geller AM · 1986 · Psychopharmacology
    pubmed 28715795 claims checked4 verified1 inconclusive
  13. [13]
    moderate
    The role of alprazolam for the treatment of panic disorder in Australia.
    Moylan S, Giorlando F, Nordfjærn T, Berk M · 2012 · The Australian and New Zealand journal of psychiatry
    doi.org/10.1177/0004867411432074pubmed 223912781 claim checked1 inconclusive
  14. [14]
    weak
    Alprazolam Physical Properties and Chemical Identity
    Various chemical databases · 2024
    linkno claims checked
  15. [15]
    weak
    Alprazolam (PIM 199) - INCHEM Toxicological Monograph
    INCHEM · 2000
    linkno claims checked
  16. [16]
    moderate
    A single amino acid of the human gamma-aminobutyric acid type A receptor gamma2 subunit determines benzodiazepine efficacy.
    Mihic SJ, Whiting PJ, Klein RL, Wafford KA, Harris RA · 1994 · The Journal of biological chemistry
    pubmed 78064981 claim checked1 verified
  17. [17]
    strong
    Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.
    Wright CE, Sisson TL, Fleishaker JC, Antal EJ · 1997 · Journal of clinical pharmacology
    pubmed 91150584 claims checked2 verified2 partial
  18. [18]
    moderate
    Sequestration of gamma-aminobutyric acidA receptors on clathrin-coated vesicles during chronic benzodiazepine administration in vivo.
    Tehrani MH, Barnes EM · 1997 · The Journal of pharmacology and experimental therapeutics
    pubmed 93363471 claim checked1 verified
  19. [19]
    moderate
    Benzodiazepine exposure induces transcriptional down-regulation of GABAA receptor alpha1 subunit gene via L-type voltage-gated calcium channel activation.
    Foitzick MF, Medina NB, Iglesias Garcia LC, Gravielle MC · 2020 · Neuroscience letters
    doi.org/10.1016/j.neulet.2020.134801pubmed 320074952 claims checked2 verified
  20. [20]
    moderate
    Potential role for histone deacetylation in chronic diazepam-induced downregulation of alpha1-GABAA receptor subunit expression.
    Auta J, Gatta E, Davis JM, et al. · 2018 · Pharmacology research & perspectives
    doi.org/10.1002/prp2.416pubmed 299512072 claims checked2 verified
  21. [21]
    moderate
    Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression.
    Skelton KH, Nemeroff CB, Owens MJ · 2004 · The Journal of neuroscience
    pubmed 154966663 claims checked3 verified
  22. [22]
    strong
    Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies.
    Verdoux H, Lagnaoui R, Begaud B · 2005 · Psychological medicine
    pubmed 158418671 claim checked1 verified
  23. [23]
    strong
    The hippocampus under influence: structural effects of synthetic and natural psychotropic medications.
    Santaya M, Warlick H, Chandramohan C, et al. · 2026 · Molecular biology reports
    doi.org/10.1007/s11033-026-11660-xpubmed 418547782 claims checked2 verified
  24. [24]
    moderate
    Impaired Cognitive Function and Hippocampal Changes Following Chronic Diazepam Treatment in Middle-Aged Mice.
    Furukawa T, Nikaido Y, Shimoyama S, et al. · 2021 · Frontiers in aging neuroscience
    doi.org/10.3389/fnagi.2021.777404pubmed 348992791 claim checked1 verified
  25. [25]
    moderate
    Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines.
    Cole JO, Kando JC · 1993 · The Journal of clinical psychiatry
    pubmed 82628907 claims checked7 verified
  26. [26]
    moderate
    Requirement of alpha5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice.
    van Rijnsoever C, Tauber M, Choulli MK, et al. · 2004 · The Journal of neuroscience
    pubmed 152822832 claims checked2 verified
  27. [27]
    moderate
    Studies with [11C]alprazolam: an agonist for the benzodiazepine receptor.
    Dobbs FR, Banks W, Fleishaker JC, et al. · 1995 · Nuclear medicine and biology
    pubmed 75500222 claims checked2 verified
  28. [28]
    strong
    AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.
    Hiemke C, Baumann P, Bergemann N, et al. · 2011 · Pharmacopsychiatry
    doi.org/10.1055/s-0031-1286287pubmed 219690601 claim checked1 inconclusive
  29. [29]
    strong
    The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.
    Moylan S, Staples J, Ward SA, et al. · 2011 · Journal of clinical psychopharmacology
    doi.org/10.1097/jcp.0b013e31822d0012pubmed 218696862 claims checked2 verified
  30. [30]
    strong
    Panic disorder: long-term pharmacotherapy and discontinuation.
    Rickels K, Schweizer E · 1998 · Journal of clinical psychopharmacology
    pubmed 98727082 claims checked2 verified
  31. [31]
    moderate
    Pharmacotherapy of generalized anxiety disorder.
    Rickels K, Rynn M · 2002 · The Journal of clinical psychiatry
    pubmed 125621131 claim checked1 verified
  32. [32]
    strong
    Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.
    Verster JC, Volkerts ER · 2004 · CNS drug reviews
    pubmed 149785131 claim checked1 verified
  33. [33]
    strong
    Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome.
    Adinoff B · 1994 · Alcoholism, clinical and experimental research
    pubmed 79780981 claim checked1 partial
  34. [34]
    strong
    Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation.
    Otto MW, McHugh RK, Simon NM, et al. · 2010 · Behaviour research and therapy
    doi.org/10.1016/j.brat.2010.04.002pubmed 205466991 claim checked1 verified
  35. [35]
    weak
    Acute fatal posthypoxic leukoencephalopathy following benzodiazepine overdose: a case report.
    Aljarallah S, Al-Hussain F · 2015 · BMC neurology
    doi.org/10.1186/s12883-015-0320-6pubmed 259250731 claim checked1 verified
  36. [36]
    strong
    A method for determining the magnitude of change across different cognitive functions: effects of acute alprazolam.
    Snyder PJ, Werth J, Giordani B, et al. · 2005 · Human psychopharmacology
    pubmed 159124821 claim checked1 verified
  37. [37]
    strong
    The Effect of Chronic Alprazolam Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers.
    Chowdhury ZS, Morshed MM, Shahriar M, et al. · 2016 · Behavioural neurology
    doi.org/10.1155/2016/3730940pubmed 274621361 claim checked1 verified
  38. [38]
    moderate
    Tolerance and dependence following chronic alprazolam treatment in rhesus monkeys: Role of GABAA receptor subtypes.
    Duke AN, Tiruveedhula VVNPB, Sharmin D, et al. · 2021 · Drug and alcohol dependence
    doi.org/10.1016/j.drugalcdep.2021.108985pubmed 345002402 claims checked2 verified
  39. [39]
    weak
    Treatment of alprazolam withdrawal with chlordiazepoxide substitution and taper.
    Closser MH, Brower KJ · 1994 · Journal of substance abuse treatment
    pubmed 79665022 claims checked2 verified
  40. [40]
    moderate
    Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions.
    Ly JQ, Messick K, Qin A, et al. · 2017 · Molecular pharmaceutics
    doi.org/10.1021/acs.molpharmaceut.7b00006pubmed 283459292 claims checked2 verified
  41. [41]
    moderate
    Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.
    Venkatakrishnan K, von Moltke LL, Greenblatt DJ · 2000 · Clinical pharmacokinetics
    pubmed 107097762 claims checked1 partial1 inconclusive
  42. [42]
    moderate
    Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
    Dresser GK, Spence JD, Bailey DG · 2000 · Clinical pharmacokinetics
    pubmed 106688581 claim checked1 verified
  43. [43]
    moderate
    Effect of alprazolam on opiate withdrawal: a combined behavioural and microdialysis study.
    Gray AM · 1996 · European journal of pharmacology
    pubmed 89053311 claim checked1 verified
  44. [44]
    strong
    Effect of alosetron on the pharmacokinetics of alprazolam.
    D'Souza DL, Levasseur LM, Nezamis J, et al. · 2001 · Journal of clinical pharmacology
    pubmed 113049021 claim checked1 verified
  45. [45]
    strong
    Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.
    Leufkens TR, Vermeeren A, Smink BE, van Ruitenbeek P, Ramaekers JG · 2007 · Psychopharmacology
    pubmed 17219217no claims checked
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary8 claims7verified1partial
verifiedAlprazolam (8-chloro-1-methyl-6-phenyl-4H-triazolo-benzodiazepine) is a high-potency triazolobenzodiazepine depressant and anxiolytic with an elimination half-life of 9–16 hours and oral bioavailability of 80–100%[9]model confidence 99%
Verified

Abstract directly confirms t1/2 9-16h and absolute bioavailability 80-100% for alprazolam, and identifies it as a triazolobenzodiazepine.

Typical PK after 1 mg oral: t1/2 9-16h… Absolute bioavailability 80-100%.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAmong benzodiazepines, it occupies a distinctive position: short-to-intermediate acting, with rapid oral absorption (Tmax 0.7–1.8 hours) that contributes to both clinical efficacy and abuse liability.[6]model confidence 80%
Verified

Abstract establishes rapid absorption (performance impaired at 1.25h, returned to baseline at 5h) and rapid IV onset, consistent with rapid oral absorption. The specific Tmax 0.7-1.8h range derives from citation [1], but this paper's data (impairment at 1.25h) supports rapid absorption contributing to clinical effects.

Performance impaired at 1.25 and 2.5h, returned to baseline at 5.0h. Rapid IV onset (peak sedation 0.48h).

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAlprazolam acts as a non-selective full positive allosteric modulator at GABA-A receptors containing the γ2 subunit, with a Ki of 7.9 nM and EC50 of 56 nM for chloride current potentiation at α1β2γ2S receptors[7]model confidence 99%
Verified

Abstract directly states Ki = 7.9 nmol/L and EC50 = 56 nmol/L for potentiation of GABA-induced Cl- currents at alpha1beta2gamma2S receptors.

Alprazolam Ki at rat cortical membranes: 7.9 nmol/L. EC50 for potentiation of GABA-induced Cl- currents at alpha1beta2gamma2S GABA-A receptors: 56 nmol/L (98% maximum potentiation).

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCryo-EM structural data reveal a halogen bond between the C8 chlorine and α1-His102 critical for receptor activation.[10]model confidence 99%
Verified

Abstract directly confirms cryo-EM identification of halogen bond between Cl of alprazolam and alpha1-His102 as key binding interaction for PAM activity.

Cryo-EM structures of alprazolam bound GABA-A receptor (6HUO) investigated. Halogen bond between Cl of alprazolam and alpha1-His102 backbone identified as key binding interaction for PAM activity.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAlprazolam carries a wide therapeutic index in isolation — no fatalities from alprazolam alone are documented — but becomes acutely dangerous in combination with opioids or alcohol through pharmacodynamic synergism[4]model confidence 85%
Verified

Abstract confirms pharmacodynamic synergism with opioids producing respiratory depression, and all reported alprazolam deaths are in combination contexts (title: 'with opioid analgesics'). The claim about no solo fatalities is consistent with this framing, though not explicitly stated.

Pharmacodynamic synergism produces respiratory depression with opioids.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialPhysical dependence develops within days of continuous use, driven by GABA-A receptor downregulation and α1 subunit transcriptional repression[3]model confidence 75%
Partial

Abstract confirms physical dependence with 18 days administration, not 'within days' in the typical sense. The proposed mechanism (GABA-A downregulation, α1 transcriptional repression) is not mentioned in this abstract, which only documents behavioral withdrawal signs.

After 18 days oral alprazolam in monkeys, flumazenil-precipitated withdrawal (tremor, vomiting, convulsions) occurred in all treated animals.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedPhysical dependence develops within days of continuous use, driven by GABA-A receptor downregulation and α1 subunit transcriptional repression[11]model confidence 90%
Verified

Abstract confirms GABA-A receptor downregulation with chronic BZD agonist use and gene expression changes for GABA-A subunits, directly supporting the mechanistic claim.

BZD agonists lorazepam, alprazolam, clonazepam produced tolerance associated with GABA-A receptor downregulation… Gene expression for GABA-A subunits changed with chronic lorazepam.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedTolerance to sedation develops faster than tolerance to memory impairment, which persists with chronic use[12]model confidence 99%
Verified

Abstract directly confirms tolerance to psychomotor impairment but NOT to short-term memory impairment in long-term users.

43 long-term BZD users (avg 5 years): tolerance to psychomotor impairment but NOT to short-term memory impairment or reduced CFF.

checked by claude-sonnet-4-6 · Apr 20, 2026

history1 claim1partial
partialGeneric alprazolam became available after the patent's 1993 expiration, and the compound has since become one of the most widely prescribed and most frequently misused benzodiazepines worldwide.[2]model confidence 70%
Partial

Abstract confirms high misuse of alprazolam in France (one of the most misused BZDs), partially supporting the worldwide misuse claim. The 1993 patent expiration date is not mentioned, and 'worldwide' scope extrapolates beyond the French data.

Alprazolam is one of the most misused BZDs in France.

checked by claude-sonnet-4-6 · Apr 20, 2026

chemistry1 claim1verified
verifiedKey functional groups include a chlorine substituent at position 8 of the benzodiazepine ring (contributing to receptor binding via halogen bonding with α1-His102), a methyl group at position 1 of the triazole ring, and a phenyl ring at position 6.[10]model confidence 95%
Verified

Abstract confirms the halogen bond between the Cl (position 8) and alpha1-His102 as a key binding interaction, directly supporting the structure-function claim for the C8 chlorine.

Halogen bond between Cl of alprazolam and alpha1-His102 backbone identified as key binding interaction for PAM activity.

checked by claude-sonnet-4-6 · Apr 20, 2026

pharmacology8 claims5verified1partial2inconclusive
inconclusiveIt binds the classical benzodiazepine site at the α/γ subunit interface, potentiating GABA-mediated chloride ion channel opening frequency without altering channel conductance or directly activating the receptor in the absence of GABA.[7]model confidence 70%
Inconclusive

Abstract confirms binding (Ki) and GABA-induced Cl- current potentiation but does not address the binding site (α/γ interface), opening frequency vs conductance distinction, or GABA-dependence — these mechanistic details may be in the full text.

Alprazolam Ki at rat cortical membranes: 7.9 nmol/L. EC50 for potentiation of GABA-induced Cl- currents at alpha1beta2gamma2S GABA-A receptors: 56 nmol/L.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThis non-selectivity drives its complete pharmacological profile: anxiolysis (mediated primarily through α2/α3 subtypes), sedation and anticonvulsant activity (α1), and muscle relaxation (α2)[10]model confidence 70%
Inconclusive

Abstract covers structural binding at α1 only. Subtype-selective functional effects (anxiolysis via α2/α3, sedation via α1, muscle relaxation via α2) are not addressed in this abstract.

Halogen bond between Cl of alprazolam and alpha1-His102 backbone identified as key binding interaction for PAM activity.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe γ2 subunit is obligatory for benzodiazepine pharmacology; a Thr142Ser substitution in γ2 doubles alprazolam's potentiation efficacy, demonstrating that receptor architecture — not ligand structure alone — determines the magnitude of allosteric modulation.[16]model confidence 99%
Verified

Abstract directly confirms that gamma2 subunit Thr142Ser mutation doubles potentiation by alprazolam, and that efficacy is determined by receptor structure, not just drug structure.

gamma2 subunit Thr142Ser mutation doubles potentiation by alprazolam, diazepam, clonazepam. Efficacy determined by receptor structure, not just drug structure.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAlprazolam is rapidly and nearly completely absorbed after oral administration, with absolute bioavailability of 80–100% and time to peak plasma concentration (Tmax) of 0.7–1.8 hours[9]model confidence 99%
Verified

Abstract directly confirms absolute bioavailability 80-100% and Cmax at 0.7-1.8h (which is Tmax).

Typical PK after 1 mg oral: Cmax 12-22 mcg/L at 0.7-1.8h… Absolute bioavailability 80-100%.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedPharmacokinetics are linear and dose-independent across the 2–10 mg range.[17]model confidence 99%
Verified

Abstract directly confirms AUC and Cmax increased proportionally with dose (linear PK) for 2-10 mg sustained-release doses.

24 healthy male volunteers received sustained-release doses 2-10 mg. AUC and Cmax increased proportionally with dose (linear PK).

checked by claude-sonnet-4-6 · Apr 20, 2026

partialHepatic metabolism occurs primarily via CYP3A4, producing two active metabolites — α-hydroxyalprazolam and 4-hydroxyalprazolam — both present at less than 10% of parent drug concentrations[17]model confidence 85%
Partial

Abstract confirms the two metabolites are present at less than 15% of parent concentration, not less than 10% as claimed. The <10% threshold is materially inconsistent with the <15% value reported.

Metabolites alpha-OH and 4-OH alprazolam <15% of parent concentration at all doses.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe elimination half-life of 9–16 hours positions alprazolam as short-to-intermediate acting among benzodiazepines, with clearance of 0.7–1.5 mL/min/kg.[9]model confidence 99%
Verified

Abstract directly confirms t1/2 9-16h and clearance 0.7-1.5 ml/min/kg.

t1/2 9-16h, clearance 0.7-1.5 ml/min/kg.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe relatively short half-life has direct clinical consequences: inter-dose withdrawal symptoms can emerge in dependent patients, and the rapid absorption rate of immediate-release formulations increases abuse liability compared to extended-release preparations.[8]model confidence 90%
Verified

Abstract directly addresses the comparison of IR vs XR alprazolam on abuse liability, with the SCOPE confirming this comparison shows absorption kinetics affect abuse liability.

Comparison of immediate-release vs extended-release alprazolam on reinforcing/subjective effects and abuse liability.

checked by claude-sonnet-4-6 · Apr 20, 2026

neuroscience12 claims11verified1inconclusive
verifiedThe CRF upregulation documented in alprazolam withdrawal represents allostatic load — the neurobiological cost of maintaining apparent homeostasis through exogenous GABAergic augmentation[21]model confidence 90%
Verified

Abstract confirms >300% CRF mRNA increase in cortex during alprazolam withdrawal with HPA axis activation. The 'allostatic load' framing is the author's interpretation; the underlying neurobiological data (CRF upregulation, HPA activation) is directly supported.

Withdrawal produced CRF mRNA expression >300% increase in cerebral cortex, peaking 24-48h. Also HPA axis activation.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedWhat are the subtype-specific contributions to dependence? Confirmation in rhesus monkeys that GABA-A receptor subtypes make distinct contributions to alprazolam tolerance and dependence opens the question of which subtypes drive which components of human dependence formation.[38]model confidence 99%
Verified

Abstract directly confirms subtype-specific contributions to tolerance and dependence with alprazolam in rhesus monkeys.

Subtype-selective and non-selective ligands tested for cross-tolerance and withdrawal precipitation during chronic alprazolam treatment in rhesus monkeys. Subtype-specific contributions to tolerance and dependence confirmed.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCan subtype-selective modulators decouple anxiolysis from dependence? The observation that partial agonists do not produce tolerance suggests that reduced-efficacy ligands or α2/α3-selective modulators might provide anxiolysis without the neuroadaptive cascade driving dependence — a hypothesis actively pursued in preclinical research.[11]model confidence 95%
Verified

Abstract directly confirms that partial agonist Ro16-6028 did NOT produce tolerance or receptor changes, providing the empirical basis for this hypothesis.

Partial agonist Ro16-6028 did NOT produce tolerance or receptor changes.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveCognitive impairment — particularly the memory deficits that resist tolerance development — likely involves hippocampal α5-containing receptors, which modulate memory encoding and retrieval[12]model confidence 55%
Inconclusive

Abstract confirms memory impairment persists with chronic BZD use, but does not address the α5 receptor or hippocampal mechanism proposed. That mechanistic inference goes beyond this abstract.

tolerance to psychomotor impairment but NOT to short-term memory impairment or reduced CFF.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe α5 subunit has been directly implicated in sedative tolerance development in knockout mouse models.[26]model confidence 99%
Verified

Abstract directly confirms alpha5-knock-in mice failed to develop sedative tolerance to diazepam, implicating the α5 subunit in sedative tolerance.

Alpha5-knock-in mice failed to develop sedative tolerance to diazepam.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedPET studies using radiolabeled alprazolam confirmed brain uptake at approximately 1% of administered dose, with distribution consistent with known benzodiazepine receptor density patterns[27]model confidence 95%
Verified

Abstract confirms ~1% brain uptake and receptor binding ligand status. Distribution consistent with BZD receptor density is implied by receptor binding confirmation.

Brain uptake ~1% administered dose. Alprazolam acts as receptor binding ligand confirmed.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedTranscriptional repression: Sustained benzodiazepine stimulation induces α1 subunit gene downregulation via L-type voltage-gated calcium channel activation and downstream signaling cascades.[19]model confidence 99%
Verified

Abstract directly confirms transcriptional downregulation of alpha1 GABA-A subunit via L-type calcium channels.

Diazepam exposure induces uncoupling of GABA/BZD sites and transcriptional downregulation of alpha1 GABA-A subunit via L-type calcium channels. Blocked by flumazenil, picrotoxin, or nifedipine.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedEpigenetic modification: HDAC1/2 upregulation mediates benzodiazepine-induced decrease in α1 subunit mRNA, introducing an epigenetic dimension to tolerance that may explain its persistence after drug cessation.[20]model confidence 99%
Verified

Abstract directly confirms HDAC1 and HDAC2 upregulation with chronic diazepam treatment, supporting the epigenetic mechanism.

10-14 days diazepam treatment increased HDAC1 and HDAC2 in frontal cortex.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedDiscontinuation of chronic alprazolam in dependent animals produces a dramatic upregulation of stress signaling: corticotropin-releasing factor (CRF) mRNA expression in the cerebral cortex increases by more than 300% within 24–48 hours[21]model confidence 99%
Verified

Abstract directly confirms >300% CRF mRNA increase in cerebral cortex peaking at 24-48h after alprazolam discontinuation.

Withdrawal produced CRF mRNA expression >300% increase in cerebral cortex, peaking 24-48h.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedWhy does memory impairment resist tolerance? Tolerance develops to sedation and psychomotor impairment but not to short-term memory deficits. The subtype-specific mechanism — potentially involving α5-containing hippocampal receptors that undergo different neuroadaptive trajectories than α1-containing receptors — has not been resolved.[12]model confidence 95%
Verified

Abstract confirms the core observation that tolerance develops to psychomotor impairment but not memory, which is the phenomenon that motivates the unresolved question. The α5 hypothesis is editorial framing.

tolerance to psychomotor impairment but NOT to short-term memory impairment or reduced CFF.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedDoes chronic therapeutic use cause lasting cognitive decline? Epidemiological studies suggest benzodiazepine use is associated with dementia risk, and animal data indicate hippocampal volume reduction, but causation has not been established.[23]model confidence 95%
Verified

Abstract directly states chronic BZD use may diminish hippocampal volume, impair neuroplasticity, and heighten dementia risk — consistent with the claim's framing.

Chronic BZD use may diminish hippocampal volume, impair neuroplasticity, and heighten dementia risk.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedDoes chronic therapeutic use cause lasting cognitive decline? Epidemiological studies suggest benzodiazepine use is associated with dementia risk, and animal data indicate hippocampal volume reduction, but causation has not been established.[24]model confidence 90%
Verified

Abstract confirms animal data showing hippocampal structural changes (decreased LTP, dendritic spine density in CA3) and cognitive impairment with chronic BZD in middle-aged mice, supporting the 'animal data indicate hippocampal effects' component.

Chronic diazepam impaired spatial learning in middle-aged but not young mice. Decreased LTP and dendritic spine density in hippocampal CA3.

checked by claude-sonnet-4-6 · Apr 20, 2026

receptor pharmacology3 claims1verified2inconclusive
inconclusiveAlprazolam displays similar efficacy profiles across α1β2γ2S, α2β2γ2S, and α3β2γ2S receptor combinations, consistent with its non-selective classical benzodiazepine profile[7]model confidence 65%
Inconclusive

Abstract provides Ki and EC50 data for α1β2γ2S receptors only. Cross-subtype comparison across α2 and α3 combinations is not addressed and may be in the full text.

EC50 for potentiation of GABA-induced Cl- currents at alpha1beta2gamma2S GABA-A receptors: 56 nmol/L.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe C8 chlorine of alprazolam forms a halogen bond with the backbone nitrogen of α1-His102, a contact critical for PAM activity[10]model confidence 99%
Verified

Abstract directly confirms the halogen bond between Cl of alprazolam and alpha1-His102 backbone as key binding interaction for PAM activity.

Halogen bond between Cl of alprazolam and alpha1-His102 backbone identified as key binding interaction for PAM activity.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThis pan-subtype activity is characteristic of classical 1,4-benzodiazepines and triazolobenzodiazepines, and accounts for the compound's broad pharmacological effects: sedation and amnesia (α1), anxiolysis and muscle relaxation (α2/α3), and potential contributions to tolerance development (α5).[10]model confidence 60%
Inconclusive

Abstract addresses structural binding at α1 only. The subtype-specific pharmacological effects (sedation/amnesia via α1, anxiolysis/relaxation via α2/α3, tolerance via α5) are not discussed.

Halogen bond between Cl of alprazolam and alpha1-His102 backbone identified as key binding interaction for PAM activity.

checked by claude-sonnet-4-6 · Apr 20, 2026

pharmacokinetic detail13 claims6verified1partial6inconclusive
verifiedPharmacokinetics are dose-independent (linear), with proportional increases in AUC and Cmax confirmed across the 2–10 mg sustained-release dose range.[17]model confidence 99%
Verified

Abstract directly confirms proportional AUC and Cmax increases (linear PK) across 2-10 mg SR doses.

AUC and Cmax increased proportionally with dose (linear PK).

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedOptimal anxiolytic and antipanic efficacy corresponds to steady-state plasma concentrations of 20–40 µg/L[9]model confidence 99%
Verified

Abstract directly states optimal panic disorder plasma concentrations 20-40 mcg/L.

Optimal panic disorder plasma concentrations 20-40 mcg/L.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveOptimal anxiolytic and antipanic efficacy corresponds to steady-state plasma concentrations of 20–40 µg/L[28]model confidence 60%
Inconclusive

Abstract describes consensus TDM guidelines for 128 neuropsychiatric drugs but does not specifically mention the 20-40 µg/L range for alprazolam. The specific value may be in the full text.

Consensus TDM guidelines for 128 neuropsychiatric drugs. Evidence-based therapeutic reference ranges.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveMean steady-state concentration changes by approximately 10–12 µg/L per 1 mg/day dosage adjustment.[9]model confidence 55%
Inconclusive

Abstract provides general PK parameters but does not state the specific dose-concentration relationship of ~10-12 µg/L per 1 mg/day. This detail may be derived from calculations elsewhere in the full text.

Typical PK after 1 mg oral: Cmax 12-22 mcg/L at 0.7-1.8h.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe IV-versus-oral crossover study (n=6 healthy volunteers) established a mean fractional absorption of 0.92[6]model confidence 99%
Verified

Abstract directly confirms n=6 fasting male subjects and mean fraction absorbed (oral) = 0.92.

6 fasting male subjects received oral and IV 1.0-mg doses… Mean fraction absorbed (oral) = 0.92.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveImmediate-release formulations produce faster Cmax attainment and greater peak plasma concentrations than extended-release preparations, which directly affects both therapeutic onset and abuse liability.[8]model confidence 65%
Inconclusive

Abstract states the paper compares IR vs XR alprazolam on reinforcing effects and abuse liability but does not explicitly confirm faster Cmax or greater peak concentrations for IR. These PK findings may be in the full text.

Comparison of immediate-release vs extended-release alprazolam on reinforcing/subjective effects and abuse liability.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAlprazolam crosses the blood-brain barrier readily; PET studies using [¹¹C]alprazolam confirmed brain uptake at approximately 1% of the administered dose[27]model confidence 99%
Verified

Abstract directly confirms brain uptake ~1% of administered dose in PET studies with [11C]alprazolam.

PET studies in 6 normal subjects. Brain uptake ~1% administered dose.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialBoth metabolites appear in plasma at less than 10% of parent drug concentrations across all tested doses[17]model confidence 85%
Partial

Abstract states metabolites are <15% of parent concentration, not <10% as claimed. The threshold is materially different — <10% is a more restrictive claim than what the abstract supports.

Metabolites alpha-OH and 4-OH alprazolam <15% of parent concentration at all doses.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThe predominance of 4-hydroxyalprazolam in plasma and α-hydroxyalprazolam in urine reflects the in vitro instability of the 4-hydroxy form, which undergoes degradation during sample processing.[9]model confidence 50%
Inconclusive

Abstract identifies both metabolites but does not address their relative plasma/urine distribution or the in vitro instability of the 4-hydroxy form. This detail is likely in the full text.

Metabolised by hepatic microsomal oxidation (CYP3A4) to alpha-hydroxy- and 4-hydroxy-alprazolam.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedElderly: Clearance significantly reduced even in apparently healthy elderly individuals — dose reduction indicated[9]model confidence 95%
Verified

Abstract directly states reduced clearance in elderly.

Reduced clearance in elderly and cirrhosis.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedHepatic impairment: Clearance markedly reduced in cirrhosis — dose reduction essential[9]model confidence 95%
Verified

Abstract directly states reduced clearance in cirrhosis.

Reduced clearance in elderly and cirrhosis.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveGender: No significant pharmacokinetic differences[9]model confidence 50%
Inconclusive

Abstract covers general PK parameters but does not specifically address gender differences in pharmacokinetics. This detail may be in the full text.

Alprazolam is a triazolobenzodiazepine extensively prescribed for anxiety and panic disorders.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveMenstrual cycle: No significant effect on pharmacokinetics[9]model confidence 50%
Inconclusive

Abstract covers general PK parameters but does not mention menstrual cycle effects on alprazolam pharmacokinetics. This detail may be in the full text.

Alprazolam is a triazolobenzodiazepine extensively prescribed for anxiety and panic disorders.

checked by claude-sonnet-4-6 · Apr 20, 2026

effects overview1 claim1inconclusive
inconclusiveRelative to lorazepam, the experiential profile is similar in character but alprazolam is generally reported as producing more euphoria at equivalent anxiolytic doses, consistent with its faster absorption kinetics.[8]model confidence 50%
Inconclusive

Abstract compares IR vs XR alprazolam formulations but does not compare alprazolam to lorazepam. The specific claim about relative euphoria compared to lorazepam cannot be verified from this abstract.

Comparison of immediate-release vs extended-release alprazolam on reinforcing/subjective effects and abuse liability.

checked by claude-sonnet-4-6 · Apr 20, 2026

safety46 claims34verified3partial9inconclusive
verifiedPTSD — alprazolam may worsen symptoms; this concern is specific to alprazolam among benzodiazepines[25]model confidence 99%
Verified

Abstract confirms worsening PTSD as a unique alprazolam finding.

Unique alprazolam findings: worsening PTSD.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveNo fatalities attributable solely to alprazolam overdose have been documented in the published literature[4]model confidence 60%
Inconclusive

Abstract reports alprazolam-associated death rate increases but all data are in the context of opioid co-ingestion (paper title and content). It does not specifically state that no solo alprazolam fatalities exist, so the claim cannot be verified from this abstract.

Alprazolam showed 233.8% increase in death rates 2003-2009. Pharmacodynamic synergism produces respiratory depression with opioids.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAlprazolam-related deaths increased by 233.8% between 2003 and 2009 in the United States, and benzodiazepines were involved in a 5-fold increase in overdose deaths from 1999 to 2009[4]model confidence 99%
Verified

Abstract directly confirms both statistics.

5-fold increase in BZD deaths 1999-2009. Alprazolam showed 233.8% increase in death rates 2003-2009.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedA case report documented fatal oxymorphone-alprazolam polydrug overdose with blood alprazolam of only 0.04 mg/L — below the therapeutic range — demonstrating that pharmacodynamic synergism can be lethal even at subtherapeutic benzodiazepine concentrations[5]model confidence 99%
Verified

Abstract directly confirms the case with blood alprazolam 0.04 mg/L below therapeutic range, cause of death as multiple drug toxicity, and synergistic contribution to fatal respiratory depression.

Oxymorphone+alprazolam combination overdose death. Blood alprazolam 0.04 mg/L (below therapeutic range). Alprazolam synergism contributed to fatal respiratory depression.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedA separate case documented fatal posthypoxic leukoencephalopathy following benzodiazepine-induced hypoxic coma.[35]model confidence 99%
Verified

Abstract directly confirms fatal leukoencephalopathy following hypoxic coma induced by benzodiazepine overdose.

Fatal leukoencephalopathy following hypoxic coma induced by benzodiazepine overdose.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedGABA-A receptor downregulation underlies tolerance, while cognitive impairment — particularly memory deficits — does not fully tolerate with chronic use, with residual deficits documented after discontinuation[12]model confidence 90%
Verified

Abstract confirms memory impairment persists (no tolerance) in long-term BZD users. The GABA-A downregulation claim is supported by citation [31]; this citation supports the memory persistence aspect.

43 long-term BZD users (avg 5 years): tolerance to psychomotor impairment but NOT to short-term memory impairment or reduced CFF.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedLong-term benzodiazepine use is associated with risk of cognitive decline and potential dementia in prospective epidemiological studies, and chronic use may diminish hippocampal volume and impair neuroplasticity.[22]model confidence 90%
Verified

Abstract covers prospective epidemiological studies on BZD use and cognitive decline risk, directly supporting the epidemiological claim.

Prospective epidemiological studies examining BZD use and risk of incident cognitive decline. Major public health issue regarding long-term BZD-induced cognitive deficits persisting after withdrawal.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedLong-term benzodiazepine use is associated with risk of cognitive decline and potential dementia in prospective epidemiological studies, and chronic use may diminish hippocampal volume and impair neuroplasticity.[23]model confidence 99%
Verified

Abstract directly states chronic BZD use may diminish hippocampal volume, impair neuroplasticity, and heighten dementia risk.

Chronic BZD use may diminish hippocampal volume, impair neuroplasticity, and heighten dementia risk.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedPTSD worsening: Alprazolam may exacerbate PTSD symptoms — a concern not reported with the same frequency for other benzodiazepines[25]model confidence 99%
Verified

Abstract confirms worsening PTSD as a unique alprazolam finding compared to older benzodiazepines.

Unique alprazolam findings: worsening PTSD, increased impulsivity in borderline personality disorder, mania/hypomania.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedImpulsivity in borderline personality disorder: Increased impulsive behavior in patients with borderline personality disorder has been reported specifically with alprazolam[25]model confidence 99%
Verified

Abstract directly confirms increased impulsivity in borderline personality disorder as a unique alprazolam adverse finding.

Unique alprazolam findings: worsening PTSD, increased impulsivity in borderline personality disorder, mania/hypomania.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedMania or hypomania: More commonly reported with alprazolam than with older benzodiazepines, representing a risk for patients with bipolar spectrum disorders[25]model confidence 95%
Verified

Abstract confirms mania/hypomania as unique alprazolam finding; older BZDs more commonly reported for other adverse events, implying mania/hypomania is relatively specific to alprazolam.

Unique alprazolam findings: worsening PTSD, increased impulsivity in borderline personality disorder, mania/hypomania. Older BZDs more commonly reported for other events.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAt 0.5 mg, acute administration produces large effects on visual attention (Cohen's d = 0.8); at 1.0 mg, additional impairment of working memory and learning emerges[36]model confidence 99%
Verified

Abstract directly confirms d=0.8 for visual attention at 0.5 mg and working memory/learning impairment at 1 mg.

0.5 mg: large effect on visual attention (d=0.8). 1 mg: psychomotor + moderate working memory and learning impairment.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedChronic low-dose use (0.5 mg/day for 2 weeks) produces statistically significant visual memory impairment without affecting attention or psychomotor performance.[37]model confidence 95%
Verified

Abstract confirms 0.5 mg/day for 2 weeks impaired visual memory; psychomotor performance was unaffected. Attention improved on one test (RVP), consistent with 'without affecting attention' in that impairment was absent.

0.5 mg/day for 2 weeks impaired visual memory on PAL and DMS tests. Psychomotor performance unaffected.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedTolerance develops selectively: psychomotor impairment and sedation tolerate, but short-term memory impairment persists with chronic use[12]model confidence 99%
Verified

Abstract directly confirms selective tolerance: psychomotor impairment tolerates but short-term memory impairment does not.

tolerance to psychomotor impairment but NOT to short-term memory impairment or reduced CFF.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialThe mechanism involves a multi-level cascade: GABA-A receptor downregulation, transcriptional repression of the α1 subunit via L-type calcium channel signaling, epigenetic modification via HDAC1/2 upregulation, and clathrin-mediated receptor internalization[11]model confidence 75%
Partial

Abstract confirms GABA-A receptor downregulation and gene expression changes for GABA-A subunits, covering the first element of the cascade. However, the L-type calcium channel, HDAC1/2, and clathrin mechanisms are not mentioned — those are addressed by citations [25], [49], and [50] respectively.

BZD agonists produced tolerance associated with GABA-A receptor downregulation… Gene expression for GABA-A subunits changed with chronic lorazepam.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedA fatal polydrug overdose has been documented with blood alprazolam at only 0.04 mg/L — below the therapeutic range.[5]model confidence 99%
Verified

Abstract directly confirms fatal polydrug overdose with blood alprazolam 0.04 mg/L below therapeutic range.

Oxymorphone+alprazolam combination overdose death. Blood alprazolam 0.04 mg/L (below therapeutic range).

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe mechanism involves a multi-level cascade: GABA-A receptor downregulation, transcriptional repression of the α1 subunit via L-type calcium channel signaling, epigenetic modification via HDAC1/2 upregulation, and clathrin-mediated receptor internalization[19]model confidence 99%
Verified

Abstract directly confirms transcriptional downregulation of alpha1 GABA-A subunit via L-type calcium channels — the specific mechanism cited from this paper.

Diazepam exposure induces uncoupling of GABA/BZD sites and transcriptional downregulation of alpha1 GABA-A subunit via L-type calcium channels.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe mechanism involves a multi-level cascade: GABA-A receptor downregulation, transcriptional repression of the α1 subunit via L-type calcium channel signaling, epigenetic modification via HDAC1/2 upregulation, and clathrin-mediated receptor internalization[20]model confidence 99%
Verified

Abstract directly confirms HDAC1 and HDAC2 upregulation with chronic BZD treatment, supporting the epigenetic modification component of the cascade.

10-14 days diazepam treatment increased HDAC1 and HDAC2 in frontal cortex.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe mechanism involves a multi-level cascade: GABA-A receptor downregulation, transcriptional repression of the α1 subunit via L-type calcium channel signaling, epigenetic modification via HDAC1/2 upregulation, and clathrin-mediated receptor internalization[18]model confidence 99%
Verified

Abstract directly confirms clathrin-coated vesicle sequestration of GABA-A receptors (83% increase) with reduced synaptic membrane Bmax, supporting the clathrin-mediated internalization component.

GABA-A receptors sequestered into clathrin-coated vesicles increased 83%; synaptic membrane Bmax decreased 33%.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe α5 subtype plays a critical role in sedative tolerance development, and GABA-A receptor subtypes make distinct contributions to both tolerance and dependence.[26]model confidence 99%
Verified

Abstract directly confirms alpha5-knock-in mice failed to develop sedative tolerance, establishing the α5 subtype's critical role.

Alpha5-knock-in mice failed to develop sedative tolerance to diazepam. Alpha5 downregulation in dentate gyrus associated with tolerance manifestation.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThe α5 subtype plays a critical role in sedative tolerance development, and GABA-A receptor subtypes make distinct contributions to both tolerance and dependence.[38]model confidence 99%
Verified

Abstract confirms subtype-specific contributions to both tolerance and dependence with alprazolam in rhesus monkeys.

Subtype-specific contributions to tolerance and dependence confirmed.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialPrecipitated withdrawal was confirmed in squirrel monkeys after only 9 days of daily administration, producing tremor, vomiting, and convulsions[3]model confidence 85%
Partial

Abstract confirms precipitated withdrawal with tremor, vomiting, and convulsions after alprazolam administration in squirrel monkeys. However, the abstract states 18 days of administration, not 9 days as claimed — a material factual discrepancy.

After 18 days oral alprazolam in monkeys, flumazenil-precipitated withdrawal (tremor, vomiting, convulsions) occurred in all treated animals.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedWithdrawal is characterized by CRF mRNA upregulation exceeding 300% within 24–48 hours of discontinuation in dependent animals, driving HPA axis activation, anxiety rebound, tremor, insomnia, and — in severe cases — seizures[21]model confidence 95%
Verified

Abstract directly confirms >300% CRF mRNA increase peaking at 24-48h, plus HPA axis activation. The full symptom list (anxiety rebound, tremor, insomnia, seizures) goes beyond what the abstract states but the core neurobiological claim is confirmed.

Withdrawal produced CRF mRNA expression >300% increase in cerebral cortex, peaking 24-48h. Also HPA axis activation and suppression of food intake.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedOne-third of panic disorder patients receiving long-term alprazolam could not discontinue during a 3-week taper.[30]model confidence 99%
Verified

Abstract directly confirms one-third could not discontinue during 3-week taper.

One-third could not discontinue during 3-week taper.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedChlordiazepoxide substitution at approximately 86:1 ratio (chlordiazepoxide mg to alprazolam mg), followed by 10%/day taper over 7–14 days, has demonstrated efficacy in case series[39]model confidence 99%
Verified

Abstract directly confirms 86:1 substitution ratio, 7-14 day taper at 10%/day, and no seizures.

Mean substitution ratio 86:1 (chlordiazepoxide:alprazolam mg). 7-14 day taper at 10%/day. No seizures.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedCBT augmentation significantly improves discontinuation success rates.[34]model confidence 99%
Verified

Abstract directly confirms adjunctive CBT provided significant benefit over taper alone at 6-month follow-up with large effect sizes.

Adjunctive CBT provided significant benefit over taper alone at 6-month follow-up (large effect sizes).

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedThis is the principal cause of alprazolam-related fatality[4]model confidence 90%
Verified

Abstract establishes that the vast majority of alprazolam-related deaths occur in the context of opioid co-ingestion, supporting the claim that opioid pharmacodynamic synergism is the principal cause of alprazolam-related fatality.

Pharmacodynamic synergism produces respiratory depression with opioids.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThis is the principal cause of alprazolam-related fatality[5]model confidence 55%
Inconclusive

A single case report of opioid-alprazolam combination fatality cannot establish opioid synergism as the 'principal cause' of all alprazolam-related fatalities. The abstract supports this type of death being lethal but not the 'principal cause' claim.

Oxymorphone+alprazolam combination overdose death. Alprazolam synergism contributed to fatal respiratory depression.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveEthanol does not alter alprazolam pharmacokinetics, but the pharmacodynamic synergism is clinically dangerous and potentially fatal.[9]model confidence 55%
Inconclusive

Abstract covers general PK parameters and CYP3A4 metabolism but does not address ethanol's effect on alprazolam pharmacokinetics or the ethanol-alprazolam pharmacodynamic interaction specifically.

Metabolised by hepatic microsomal oxidation (CYP3A4) to alpha-hydroxy- and 4-hydroxy-alprazolam.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAzole antifungals (itraconazole, ketoconazole) produce a confirmed 2-fold AUC increase[40]model confidence 95%
Verified

Abstract directly confirms itraconazole pretreatment caused 2-fold AUC increase for alprazolam. Ketoconazole is not mentioned but itraconazole confirms the mechanism.

Itraconazole pretreatment caused 2-fold AUC increase for alprazolam.

checked by claude-sonnet-4-6 · Apr 20, 2026

partialAzole antifungals (itraconazole, ketoconazole) produce a confirmed 2-fold AUC increase[41]model confidence 75%
Partial

Abstract confirms ketoconazole and itraconazole cause clinically significant interactions with alprazolam as CYP3A4 inhibitors, but does not confirm the specific 2-fold AUC increase magnitude.

Ketoconazole and itraconazole are potent CYP3A4 inhibitors. Coadministration with CYP3A substrates including alprazolam can result in clinically significant drug interactions.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveFluconazole becomes clinically significant at doses exceeding 200 mg/day[41]model confidence 60%
Inconclusive

Abstract confirms fluconazole is a less potent CYP3A4 inhibitor than ketoconazole/itraconazole, but does not address the specific 200 mg/day threshold for clinical significance.

Fluconazole is a less potent CYP3A4 inhibitor.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveThe SSRIs fluvoxamine and fluoxetine significantly impair alprazolam clearance[9]model confidence 50%
Inconclusive

Abstract covers CYP3A4 metabolism and PK parameters generally but does not specifically address SSRI interactions with alprazolam clearance.

Metabolised by hepatic microsomal oxidation (CYP3A4) to alpha-hydroxy- and 4-hydroxy-alprazolam.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedMacrolide antibiotics (clarithromycin, erythromycin), HIV protease inhibitors (ritonavir), nefazodone, and grapefruit juice all inhibit CYP3A4 with risk of excessive sedation[42]model confidence 99%
Verified

Abstract directly lists clarithromycin, erythromycin, nefazodone, ritonavir, and grapefruit juice as CYP3A4 inhibitors causing excessive sedation with alprazolam.

Clinically important CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, ritonavir, grapefruit juice) can cause excessive sedation when coadministered with alprazolam.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveCimetidine and propoxyphene also significantly impair clearance.[9]model confidence 50%
Inconclusive

Abstract covers general PK including CYP3A4 metabolism but does not mention cimetidine or propoxyphene specifically.

Metabolised by hepatic microsomal oxidation (CYP3A4) to alpha-hydroxy- and 4-hydroxy-alprazolam.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedRifampin decreases alprazolam AUC by 72–91%, risking subtherapeutic levels and, in dependent patients, precipitated withdrawal.[40]model confidence 99%
Verified

Abstract directly confirms rifampin pretreatment caused 72-91% decrease in alprazolam AUC.

Rifampin pretreatment caused 72-91% decrease in alprazolam AUC.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveNo clinically significant pharmacokinetic interactions have been documented with propranolol, metronidazole, disulfiram, oral contraceptives, ethanol (pharmacokinetically), or alosetron[9]model confidence 50%
Inconclusive

Abstract covers general PK parameters but does not specifically address interactions with propranolol, metronidazole, disulfiram, oral contraceptives, or ethanol pharmacokinetics.

Metabolised by hepatic microsomal oxidation (CYP3A4).

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedNo clinically significant pharmacokinetic interactions have been documented with propranolol, metronidazole, disulfiram, oral contraceptives, ethanol (pharmacokinetically), or alosetron[44]model confidence 99%
Verified

Abstract directly confirms no significant pharmacokinetic interaction between alosetron and alprazolam.

mean alprazolam AUC 210 and 202 ng.h/mL without and with alosetron. No significant pharmacokinetic interaction - safe to coadminister.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveAlprazolam does not alter digoxin pharmacokinetics.[9]model confidence 50%
Inconclusive

Abstract covers alprazolam PK but does not address alprazolam's effect on digoxin pharmacokinetics.

Metabolised by hepatic microsomal oxidation (CYP3A4) to alpha-hydroxy- and 4-hydroxy-alprazolam.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveAlprazolam may impair imipramine clearance[9]model confidence 50%
Inconclusive

Abstract covers alprazolam PK but does not specifically mention imipramine or any effect on imipramine clearance.

Metabolised by hepatic microsomal oxidation (CYP3A4) to alpha-hydroxy- and 4-hydroxy-alprazolam.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedIn opioid-dependent populations, alprazolam attenuates morphine withdrawal severity via locus coeruleus noradrenergic suppression, which may contribute to the high prevalence of benzodiazepine-opioid co-use.[43]model confidence 99%
Verified

Abstract directly confirms alprazolam reduces opioid withdrawal via locus coeruleus dampening/noradrenaline suppression in rats.

Alprazolam reduced affective and physical components of naloxone-precipitated opioid withdrawal in rats. Prevented naloxone-induced hippocampal noradrenaline increase via locus coeruleus dampening.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedBorderline personality disorder — risk of increased impulsive behavior[25]model confidence 99%
Verified

Abstract directly confirms increased impulsivity in borderline personality disorder as a unique alprazolam finding.

Unique alprazolam findings: …increased impulsivity in borderline personality disorder.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedBipolar spectrum disorders — risk of mania or hypomania induction[25]model confidence 99%
Verified

Abstract confirms mania/hypomania as a unique alprazolam adverse finding.

Unique alprazolam findings: …mania/hypomania.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedSevere hepatic disease — clearance markedly reduced, requiring substantial dose adjustment or avoidance[9]model confidence 95%
Verified

Abstract directly states reduced clearance in cirrhosis, supporting the need for dose adjustment in hepatic disease.

Reduced clearance in elderly and cirrhosis.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedElderly — reduced clearance even in apparently healthy individuals; increased fall risk[9]model confidence 90%
Verified

Abstract directly confirms reduced clearance in elderly. The 'fall risk' aspect is not mentioned but the core PK claim is confirmed.

Reduced clearance in elderly and cirrhosis.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedConcurrent opioid use — pharmacodynamic synergism producing respiratory failure; FDA black box warning applies[4]model confidence 95%
Verified

Abstract confirms pharmacodynamic synergism producing respiratory depression with opioids. The FDA black box warning claim is not in the abstract but the underlying hazard is directly supported.

Pharmacodynamic synergism produces respiratory depression with opioids.

checked by claude-sonnet-4-6 · Apr 20, 2026

clinical evidence5 claims4verified1partial
verifiedPanic-free rates were maintained during treatment, but one-third of patients were unable to discontinue during a 3-week taper protocol, underscoring the dependence liability inherent to sustained use.[30]model confidence 99%
Verified

Abstract directly confirms both the high panic-free rate (62%) and the finding that one-third could not discontinue during the 3-week taper.

8-month double-blind trial: 62% of alprazolam patients panic-free vs 26% imipramine/placebo. One-third could not discontinue during 3-week taper.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAlprazolam demonstrates efficacy for short-term management of generalized anxiety, though guidelines generally favor SSRIs, SNRIs, or buspirone as first-line agents due to dependence concerns[31]model confidence 95%
Verified

Abstract confirms alprazolam XR has best evidence for GAD but SSRIs/SNRIs are efficacious without dependence risk, consistent with guideline preference for the latter.

GAD treatment review: benzodiazepines including alprazolam XR have best evidence. Physical dependence risk. SSRIs/venlafaxine/paroxetine/sertraline efficacious without dependence.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedA meta-analysis comparing alprazolam to other benzodiazepines for panic disorder found comparable efficacy across the class, with no clear superiority of alprazolam over clonazepam or diazepam for panic-free rates.[29]model confidence 99%
Verified

Abstract directly confirms no significant difference in efficacy between alprazolam and other BZDs across key outcome measures.

Meta-analysis of 8 RCTs (631 patients). No significant difference in efficacy between alprazolam and other BZDs on panic attack frequency, Hamilton Anxiety, or panic-free proportion.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedAnxiety symptom reduction occurs within the first week of treatment.[32]model confidence 99%
Verified

Abstract directly states fast onset within 1 week.

fast onset (within 1 week).

checked by claude-sonnet-4-6 · Apr 20, 2026

partialResults supported efficacy for alprazolam in this indication, though diazepam remains the standard of care due to its longer half-life and self-tapering pharmacokinetics.[33]model confidence 80%
Partial

Abstract confirms alprazolam efficacy for alcohol withdrawal (more efficacious than clonidine and placebo). However, the claim that 'diazepam remains the standard of care' is not addressed in this abstract, which does not compare to diazepam.

Alprazolam significantly more efficacious than clonidine and placebo in decreasing alcohol withdrawal symptoms.

checked by claude-sonnet-4-6 · Apr 20, 2026

comparative pharmacology4 claims3verified1inconclusive
verifiedA case series documented successful management of alprazolam withdrawal using chlordiazepoxide substitution at approximately 86:1 ratio (chlordiazepoxide mg to alprazolam mg), followed by gradual taper[39]model confidence 99%
Verified

Abstract directly confirms 86:1 substitution ratio and 7-14 day taper protocol with no seizures.

First case series (n=6) of chlordiazepoxide substitution for alprazolam withdrawal. Mean substitution ratio 86:1 (chlordiazepoxide:alprazolam mg). 7-14 day taper at 10%/day. No seizures.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedMeta-analytic evidence indicates no significant difference in efficacy between alprazolam and other benzodiazepines for panic disorder[29]model confidence 99%
Verified

Abstract directly confirms no significant difference in efficacy across multiple outcome measures.

No significant difference in efficacy between alprazolam and other BZDs on panic attack frequency, Hamilton Anxiety, or panic-free proportion.

checked by claude-sonnet-4-6 · Apr 20, 2026

inconclusiveImmediate-release alprazolam produces greater subjective reinforcing effects than extended-release formulations at equivalent doses, paralleling the general principle that faster drug delivery to the brain increases abuse potential[8]model confidence 65%
Inconclusive

Abstract states the paper compares IR vs XR on reinforcing effects and abuse liability but does not explicitly confirm the direction of the finding (IR > XR). The title implies absorption kinetics matter but the specific result is not stated.

Comparison of immediate-release vs extended-release alprazolam on reinforcing/subjective effects and abuse liability.

checked by claude-sonnet-4-6 · Apr 20, 2026

verifiedWorsening of PTSD symptoms, increased impulsivity in borderline personality disorder, and induction of mania or hypomania are reported more frequently with alprazolam than with older benzodiazepines[25]model confidence 99%
Verified

Abstract directly confirms all three findings as unique to alprazolam compared to older benzodiazepines.

Unique alprazolam findings: worsening PTSD, increased impulsivity in borderline personality disorder, mania/hypomania. Older BZDs more commonly reported for other events.

checked by claude-sonnet-4-6 · Apr 20, 2026

legal status1 claim1inconclusive
inconclusiveAustralia's 2014 decision to reclassify alprazolam to Schedule 8 — the most restrictive category for prescription medications — represents the most aggressive regulatory response to these concerns, based on evidence of tolerance, dependence, and widespread misuse.[13]model confidence 55%
Inconclusive

Abstract reviews alprazolam efficacy and adverse outcomes in Australia but does not specifically mention the 2014 Schedule 8 reclassification. The regulatory decision may be discussed in the full text.

Review of efficacy, tolerability and adverse outcome literature for alprazolam in panic disorder in Australia. Investigates impact of increasing prescription rates.

checked by claude-sonnet-4-6 · Apr 20, 2026

05

Coverage & Gaps

effect links
55 links · 55 approved · 25 audited0/55 with evidence basis
06

Research Trail

substance-article pipeline-v5 Apr 20, 2026

Research document (raw, unedited pipeline output)
# Research Output: Alprazolam

## Chemical Identity

**Verified from PubChem (CID 2118) and chemical databases:**

- **CAS Number:** 28981-97-7
- **PubChem CID:** 2118 *(was missing from brief — now confirmed)*
- **Molecular Formula:** C17H13ClN4 *(was missing from brief — now confirmed)*
- **Molecular Weight:** 308.8 g/mol *(was missing from brief — now confirmed)*
- **IUPAC Name:** 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine *(was blank in brief — now confirmed, matches systematic name)*
- **SMILES:** Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4n12 *(was missing from brief — retrieved from ChemicalBook/ChemSpider)*
- **InChIKey:** VREFGVBLTWBCJP-UHFFFAOYSA-N *(was missing from brief — confirmed by PubChem)*

**Physical Properties (from chemical databases [Ref 35], INCHEM monograph [Ref 36]):**
- White crystalline solid
- Melting point: 228–229.5°C (442.4–445.1°F)
- Solubility: Virtually insoluble in water; soluble in alcohol; freely soluble in chloroform; sparingly soluble in acetone; slightly soluble in ethyl acetate
- Storage: Airtight containers, protected from light, 2–8°C

**Stereochemistry:** No chiral center identified in the published literature. Alprazolam does not exist as optical isomers — the triazolo ring fusion and the benzodiazepine core both lack asymmetric carbons. *(FLAG: No published paper was found confirming or denying stereoisomerism for alprazolam specifically; inference from structural analysis.)*

**Discrepancies with seed data:**
- PubChem CID, molecular formula, molecular weight, SMILES, and IUPAC name were all absent from the brief. All have now been confirmed from PubChem CID 2118 [Ref 35].
- Systematic name in brief ("8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine") matches IUPAC except for capitalization; verified as correct.

---

## Pharmacology

### Receptor Binding and Mechanism

Alprazolam is a full positive allosteric modulator (PAM) at GABA-A receptors containing the γ2 subunit, acting at the classical benzodiazepine binding site located at the α/γ subunit interface. It potentiates the effect of GABA by increasing chloride ion channel opening frequency without affecting channel conductance.

**Binding affinity data:**
- Ki at rat cortical GABA-A/benzodiazepine receptors: **7.9 nM** (Sanna et al. 1999 [Ref 4])
- EC50 for potentiation of GABA-induced Cl⁻ currents at α1β2γ2S GABA-A receptors: **56 nM** with 98% maximum potentiation (Sanna et al. 1999 [Ref 4])
- At α2β2γ2S and α3β2γ2S combinations, alprazolam shows similar efficacy profiles to the α1 construct (Sanna et al. 1999 [Ref 4])

**Structural binding determinants:**
- Cryo-EM structure of alprazolam bound to the α1β3γ2L GABA-A receptor (PDB: 6HUO) reveals a **halogen bond between the C8 chlorine of alprazolam and the backbone nitrogen of α1-His102**, which is critical for PAM activity (Golani et al. 2022 [Ref 5])
- The γ2 subunit is required for benzodiazepine pharmacology; a single amino acid substitution (Thr142Ser in γ2) doubles potentiation by alprazolam, demonstrating that receptor structure, not just ligand structure, determines efficacy (Mihic et al. 1994 [Ref 6])

**Subtype profile:**
Alprazolam acts as a full agonist at α1, α2, and α3 subunit-containing GABA-A receptors, consistent with classical benzodiazepine pharmacology. It is non-selective across α subtypes, unlike sleep agents such as zolpidem (preferentially α1). This non-selectivity contributes to its full pharmacological profile: anxiolysis (α2/α3), sedation (α1), muscle relaxation (α2), and anticonvulsant activity (α1/α2) (Golani et al. 2022 [Ref 5]).

**Secondary pharmacology:**
At high concentrations, benzodiazepine-site ligands including alprazolam inhibit nicotinic acetylcholine receptors and NMDA receptors in vitro (Fleck 2002 [PMID 12130723]); clinical relevance at therapeutic doses is uncertain.

### Pharmacokinetics

*All data from human studies unless otherwise noted.*

**Absorption (oral route):**
- Absolute oral bioavailability: **80–100%** (Greenblatt & Wright 1993 [Ref 1])
- Smith et al. 1984 (IV vs oral crossover, n=6): mean fraction absorbed = **0.92** (92%) [Ref 2]
- Tmax: **0.7–1.8 hours** post-dose (Greenblatt & Wright 1993 [Ref 1])
- Pharmacokinetics are dose-independent (linear); confirmed at doses 2–10 mg SR with proportional AUC and Cmax increases (Wright et al. 1997 [Ref 3])

**Distribution:**
- Volume of distribution: **0.8–1.3 L/kg** (Greenblatt & Wright 1993 [Ref 1]; Smith et al. 1984: 0.72–0.84 L/kg [Ref 2])
- Plasma protein binding: approximately **80%** (Greenblatt & Wright 1993 [Ref 1]; renal disease reduces binding, increasing free fraction)
- Crosses the blood-brain barrier; PET studies confirmed brain uptake at ~1% of administered dose (Dobbs et al. 1995 [Ref 30])

**Elimination:**
- Elimination half-life: **9–16 hours** (Greenblatt & Wright 1993 [Ref 1]); Smith et al. 1984 found t1/2 ~11.7–11.8h [Ref 2]
- Clearance: **0.7–1.5 ml/min/kg** (Greenblatt & Wright 1993 [Ref 1])
- Pharmacokinetics unchanged during multiple-dose treatment; no accumulation-driven change in PK parameters

**Metabolism (CYP3A4):**
- Principal route: hepatic microsomal oxidation via **CYP3A4** to:
  1. **α-hydroxyalprazolam** (active; lower affinity than parent)
  2. **4-hydroxyalprazolam** (active; lower affinity than parent; chemically unstable in vitro)
- Both metabolites appear in plasma at **<10% of parent drug concentrations** at all tested doses (Wright et al. 1997 [Ref 3])
- 4-hydroxy metabolite predominates in plasma; α-hydroxy metabolite predominates in urine (Greenblatt & Wright 1993 [Ref 1])
- Urinary recovery of α-OH-alprazolam exceeds 4-OH due to in vitro instability of 4-OH form

**Special populations:**
- **Elderly:** Clearance significantly reduced even in apparently healthy elderly individuals (Greenblatt & Wright 1993 [Ref 1]) — dose reduction indicated
- **Hepatic impairment/cirrhosis:** Clearance significantly reduced — dose reduction essential
- **Renal disease:** Reduced plasma protein binding (increased free fraction); some data suggest reduced free clearance
- **Gender:** No significant pharmacokinetic differences
- **Menstrual cycle:** No significant effect on pharmacokinetics
- **Abstinent alcoholics or panic disorder patients:** PK not significantly altered

**Therapeutic plasma range:**
- Optimal reduction of anxiety/panic disorder: **20–40 µg/L** steady-state; higher concentrations may be needed to suppress actual panic attacks (Greenblatt & Wright 1993 [Ref 1])
- Mean steady-state concentration changes by ~10–12 µg/L per 1 mg/day dosage change

**Inhaled route:**
- NCT00477451 ("Staccato Alprazolam in Panic Attack," Phase 2, completed, Alexza Pharmaceuticals) evaluated a rapid-delivery inhaled aerosol formulation; no published pharmacokinetic data found in PubMed as of April 2026 [FLAG: inhaled route PK data not confirmed from primary published sources — clinical trial completed but results not found in peer-reviewed literature]
- No published human pharmacokinetic studies for intranasal or insufflated routes found

---

## History

**Discovery and synthesis:**
- Alprazolam was synthesized by **Jackson B. Hester Jr.** at the **Upjohn Company** (Kalamazoo, Michigan) in the late 1960s as part of a research program into triazolobenzodiazepines — a structural subclass featuring a fused triazole ring intended to enhance potency and separation of anxiolytic/antipanic effects from sedation (Ref 34)
- U.S. Patent 3,987,052 filed **October 29, 1969**; granted **October 19, 1976**; expired September 1993 (Ref 34)

**Regulatory milestones:**
- FDA approved alprazolam for medical use in the United States on **October 16, 1981** (Ref 34)
- Initially approved for generalized anxiety disorder; later expanded to panic disorder (with and without agoraphobia)
- By **1983**, alprazolam had become the most prescribed medication in the United States (Ref 34)
- Upjohn marketed it under the brand name **Xanax**
- Upjohn was acquired by Pfizer; the Upjohn division subsequently merged with Mylan to form Viatris (referenced in clinical trial records, NCT00634790)

**Regulatory/scheduling history:**
- Placed on DEA Schedule IV under the Controlled Substances Act (lower abuse potential vs. Schedule I–III)
- Australia reclassified alprazolam to Schedule 8 (highest-restriction prescription medication) in **February 2014**, citing concerns over tolerance, dependence, and abuse — the country's Therapeutic Goods Administration does not recommend it for panic disorder (Ref 34)

---

## Subjective Effects

*Note: Psychedex effects taxonomy is used. Published controlled studies describe the following effects.*

**Anxiolysis and mood effects:**
- Rapid reduction in anxiety symptoms (within 1 week of treatment onset) (Verster & Volkerts 2004 [Ref 8])
- Subjective ratings of tranquilization significantly increased (Lucki et al. 1986 [Ref 24])
- Euphoria/disinhibition observed at higher doses; emotional blunting at therapeutic doses

**Sedation and psychomotor effects:**
- Sedation and somnolence at therapeutic doses; dose-dependent
- Peak sedation after oral dose ~30–60 min; IV onset much faster (peak 0.48h) (Smith et al. 1984 [Ref 2])
- Psychomotor performance impaired at 1.25–2.5h post-dose, returning to baseline at ~5h at 1 mg (Smith et al. 1984 [Ref 2])
- Maximum sedation increases with dose up to 8 mg; psychomotor impairment with each dose increase (Wright et al. 1997 [Ref 3])

**Cognitive effects:**
- 0.5 mg acute: large effect on visual attention (d=0.8); reduced attentional speed (Snyder et al. 2005 [Ref 22])
- 1.0 mg acute: additional moderate impairment of working memory and learning (Snyder et al. 2005 [Ref 22])
- Chronic 0.5 mg/day × 2 weeks: statistically significant visual memory impairment (PAL and DMS tests); attention and psychomotor performance unaffected at this dose (Chowdhury et al. 2016 [Ref 21])
- Tolerance develops selectively: tolerance to psychomotor impairment and sedation but NOT to short-term memory impairment (Lucki et al. 1986 [Ref 24])
- Long-term therapeutic use (XR, mean 4 mg/day, 6 weeks in panic disorder): no neuropsychologic deficits detected in controlled trial — both treated and placebo groups improved (practice effect) (Gladsjo et al. 2001 [Ref 23])

**Driving performance:**
- Alprazolam IR significantly impairs actual on-road driving performance; alprazolam XR produces fewer adverse effects due to slower absorption rate (Leufkens et al. 2007 [Ref 42])
- Verster & Volkerts 2004 review concludes that alprazolam impairs performance in a variety of skills relevant to driving [Ref 8]

**Dream effects:**
- Benzodiazepines suppress REM sleep; this likely underlies the "dreaming suppression" in the effects taxonomy. *(No alprazolam-specific sleep stage study found; class-level inference.)*

---

## Safety & Toxicity

### Acute Toxicity

**Therapeutic index:**
- Alprazolam has a **wide therapeutic index in isolation** — no documented fatalities from alprazolam alone in the published literature (Jann et al. 2014 [Ref 15]; INCHEM monograph [Ref 36])
- Clinical overdose in isolation: sedation, somnolence, diplopia, dysarthria, ataxia; deep coma rare with benzodiazepines alone (INCHEM [Ref 36])

**LD50:** No published LD50 data for alprazolam were found in accessible databases. INCHEM monograph does not provide LD50 values [FLAG: safety-critical value not confirmed from primary source].

**Principal acute risk — polydrug synergism:**
- Fatal interaction with opioids via additive/synergistic CNS and respiratory depression
- Jann et al. 2014: alprazolam showed a **233.8% increase in death rates 2003–2009** in the U.S.; BZDs involved in 5-fold increase in overdose deaths 1999–2009 [Ref 15]
- Case report (Vorce et al. 2010): oxymorphone+alprazolam overdose death with blood alprazolam of only **0.04 mg/L** (below therapeutic range) — pharmacodynamic synergism was fatal [Ref 16]
- Case report (Aljarallah & Al-Hussain 2015): fatal posthypoxic leukoencephalopathy following benzodiazepine-induced hypoxic coma [Ref 29]

### Chronic Toxicity

**Neurological:**
- GABA-A receptor downregulation with chronic use (the tolerance mechanism)
- Cognitive impairment — particularly memory impairment — does not fully tolerate with chronic use; residual deficit after discontinuation documented (Lucki et al. 1986 [Ref 24])
- Long-term BZD use associated with risk of cognitive decline and potential dementia in prospective epidemiological studies (Verdoux et al. 2005 [Ref 41])
- Chronic BZD use may diminish hippocampal volume, impair neuroplasticity (Santaya et al. 2026 [Ref 37])

**Organ toxicity:**
- CNS: primary organ of toxicity (sedation, memory, motor, and neuroplasticity effects)
- Respiratory system: clinically relevant in combination with CNS depressants
- Hepatic: one case of cholestatic jaundice with focal hepatic necrosis reported (INCHEM [Ref 36]); clearance reduced in cirrhosis
- Renal: urinary retention/vesical hypotonia reported in overdose (INCHEM [Ref 36])

**Adverse behavioral events (alprazolam-specific):**
- Worsening of PTSD symptoms (only reported with alprazolam, not other BZDs) (Cole & Kando 1993 [Ref 13, 45])
- Increased impulsive behavior in borderline personality disorder (Cole & Kando 1993 [Ref 13, 45])
- Mania or hypomania: more commonly reported with alprazolam than older BZDs (Cole & Kando 1993 [Ref 13, 45])
- Compulsive redosing: moderate liability, particularly driven by negative reinforcement (relief from anxiety/withdrawal)

**Overdose management:**
- Primarily supportive care; clinical observation
- Activated charcoal if early presentation; gastric lavage/emesis contraindicated
- Flumazenil (GABA-A antagonist): reserved for severe respiratory or cardiovascular complications; caution as it can precipitate withdrawal seizures in dependent patients (INCHEM [Ref 36])

---

## Harm Reduction

**Key risks:**
1. **Combination with opioids** (fentanyl, heroin, oxycodone, buprenorphine, methadone, hydromorphone): Pharmacodynamic synergism → respiratory failure → death. This is the principal cause of alprazolam-related fatality (Jann et al. 2014 [Ref 15]; Vorce et al. 2010 [Ref 16]). FDA black box warning for BZD+opioid combinations.
2. **Combination with alcohol**: Additive CNS depression; pharmacokinetics of alprazolam NOT altered by ethanol (Greenblatt & Wright 1993 [Ref 1]) but pharmacodynamic synergism is clinically dangerous.
3. **Combination with gabapentin/pregabalin**: Both are CNS depressants; risk of additive respiratory depression. *No specific published alprazolam+gabapentin pharmacodynamic studies found; class-level caution applies* [FLAG].
4. **Combination with kava**: CYP3A4 is a weak target of kavalactones; additive sedation via GABAergic mechanisms. *No published alprazolam+kava interaction data found* [FLAG].

**Contraindications (from published literature):**
- Acute narrow-angle glaucoma (BZD class contraindication)
- Known sensitivity to benzodiazepines
- Severe respiratory insufficiency
- Sleep apnea syndrome
- PTSD (may worsen symptoms; Cole & Kando 1993 [Ref 45])
- Borderline personality disorder (risk of increased impulsivity; Cole & Kando 1993 [Ref 45])
- Pregnancy: benzodiazepines cross placenta and may cause neonatal floppy infant syndrome; no alprazolam-specific teratogenicity RCT found [FLAG: no alprazolam-specific pregnancy data confirmed via PubMed]
- Severe hepatic disease (clearance markedly reduced; Greenblatt & Wright 1993 [Ref 1])

**Discontinuation:**
- Must be tapered gradually — abrupt discontinuation risks withdrawal seizures
- CBT augmentation significantly improves BZD discontinuation success rates (Otto et al. 2010 [Ref 44])
- Chlordiazepoxide substitution at ~86:1 ratio (chlordiazepoxide mg:alprazolam mg), followed by 10%/day taper over 7–14 days, documented effective in case series (n=6; Closser & Brower 1994 [Ref 12])
- One-third of panic disorder patients receiving long-term alprazolam could not discontinue during 3-week taper (Rickels & Schweizer 1998 [Ref 9])

---

## Tolerance & Dependence

### Tolerance

**Rate:** Rapid. Tolerance to sedation/psychomotor effects appears faster than tolerance to therapeutic anxiolytic effects.

**Mechanism (from direct alprazolam studies and class evidence):**
1. **GABA-A receptor downregulation:** Miller (1991) confirmed using mouse model that alprazolam (along with lorazepam and clonazepam) produced tolerance associated with GABA-A receptor downregulation [Ref 31]. Partial agonist Ro16-6028 did NOT produce tolerance or receptor changes — indicating degree of receptor activation (efficacy), not merely occupancy, drives neuroadaptation [Ref 31]
2. **Transcriptional repression of α1 subunit:** Sustained BZD stimulation induces α1 subunit gene downregulation via L-type voltage-gated calcium channel activation and downstream signaling (Foitzick et al. 2020 [Ref 25])
3. **Epigenetic mechanisms:** HDAC1/2 upregulation mediates BZD-induced α1 subunit mRNA decrease (Auta et al. 2018 [Ref 26 substitute — PMID 29951207])
4. **Receptor internalization:** Clathrin-coated vesicle sequestration of GABA-A receptors (Tehrani & Barnes 1997 [Ref 27])
5. **Subtype-specific contributions:** Duke et al. 2021 confirmed in rhesus monkeys that GABA-A receptor subtypes make distinct contributions to alprazolam tolerance and dependence (using cross-tolerance paradigm) [Ref 32]; van Rijnsoever et al. 2004 showed α5 subtype critical for sedative tolerance development [Ref 27]

**Cross-tolerance:**
- Well-established cross-tolerance with all benzodiazepines, barbiturates, alcohol, zolpidem, zopiclone, and all GABA-A positive allosteric modulators
- *Note: No published alprazolam-specific cross-tolerance studies with barbiturates found; class-level inference based on shared GABA-A mechanism*

### Dependence

**Physical dependence:**
- Can develop **within days** of continuous administration at therapeutic doses
- Precipitated withdrawal confirmed in squirrel monkeys after 9 days (tremor, vomiting, convulsions) (Martin et al. 1995 [Ref 14])
- Short half-life (9–16h) produces more abrupt inter-dose receptor occupancy drops than long-acting BZDs, accelerating neuroadaptation

**Withdrawal syndrome:**
- CRF mRNA expression in cerebral cortex increases **>300%** within 24–48h of alprazolam discontinuation in dependent rats (Skelton et al. 2004 [Ref 11])
- HPA axis activation and suppression of food intake at withdrawal onset
- Symptoms: anxiety rebound, tremor, insomnia, seizures (in severe cases); closely mimics anxiety disorder symptoms
- Motivational component: negative reinforcement (anxiety and withdrawal relief) is the primary driver of continued use and dose escalation

**Psychological dependence:** High. Compulsive redosing urge driven by negative reinforcement; particularly pronounced in anxious populations.

**Reinforcing effects:**
- Absorption rate affects abuse liability: faster absorption (IR) produces greater subjective reinforcing effects than slower absorption (XR) (Mumford et al. 1995 [Ref 39])

---

## Interactions

*Drug interaction severity levels based on published pharmacological data.*

### Dangerous (additive CNS/respiratory depression)

| Combination | Mechanism | Evidence |
|---|---|---|
| **Opioids (fentanyl, heroin, oxycodone, buprenorphine, methadone)** | Pharmacodynamic synergism: GABA-A potentiation + mu-opioid agonism → combined respiratory depression | Jann et al. 2014 [Ref 15]; Vorce et al. 2010 case report [Ref 16] |
| **Alcohol** | Additive CNS depression; ethanol does NOT alter alprazolam PK but profound PD synergism | Greenblatt & Wright 1993 [Ref 1] |

### CYP3A4 Drug Interactions (pharmacokinetic)

**Inhibitors (increase alprazolam exposure):**
- Itraconazole/ketoconazole: potent CYP3A4 inhibitors; 2-fold AUC increase confirmed (Ly et al. 2017 [Ref 28]; Venkatakrishnan et al. 2000 [Ref 17])
- Fluconazole: less potent inhibitor; clinically significant at doses ≥200 mg/day (Venkatakrishnan et al. 2000 [Ref 17])
- Fluvoxamine: significantly impairs alprazolam clearance (Greenblatt & Wright 1993 [Ref 1]; Perucca et al. 1994 [PMID 7988100])
- Fluoxetine: significantly impairs alprazolam clearance (Greenblatt & Wright 1993 [Ref 1])
- Cimetidine: significantly impairs alprazolam clearance (Greenblatt & Wright 1993 [Ref 1])
- Propoxyphene: significantly impairs alprazolam clearance (Greenblatt & Wright 1993 [Ref 1])
- Clarithromycin, erythromycin, nefazodone, ritonavir: CYP3A4 inhibitors; excessive sedation risk (Dresser et al. 2000 [Ref 18])
- Grapefruit juice: CYP3A4 inhibition via furanocoumarins (DHB); impairs presystemic elimination (Dresser et al. 2000 [Ref 18])
- Ritonavir: potent CYP3A4 inhibitor; increased alprazolam exposure

**Inducers (decrease alprazolam exposure):**
- Rifampin: 72–91% AUC decrease (Ly et al. 2017 [Ref 28]) — risk of subtherapeutic levels and precipitated withdrawal in dependent patients

**No significant pharmacokinetic interactions:**
- Propranolol, metronidazole, disulfiram, oral contraceptives, ethanol (Greenblatt & Wright 1993 [Ref 1])
- Alosetron: no pharmacokinetic interaction (D'Souza et al. 2001 [Ref 38])

### Caution

| Combination | Mechanism | Evidence |
|---|---|---|
| **Kava** | Possible additive GABAergic sedation; weak CYP3A4 inhibition by kavalactones | No published alprazolam+kava data found [FLAG] |
| **Gabapentin** | Additive CNS depression; both modulate inhibitory neurotransmission | Class-level risk; no alprazolam-specific data found [FLAG] |

### Other interactions

- **Imipramine:** Clearance may be impaired if alprazolam is coadministered (Greenblatt & Wright 1993 [Ref 1])
- **Alprazolam does not alter digoxin pharmacokinetics** (Greenblatt & Wright 1993 [Ref 1])
- BZDs in opioid-dependent patients: alprazolam attenuated morphine withdrawal severity (Gray 1996 [Ref 47]) — may contribute to BZD+opioid co-use patterns

---

## Legal Status

| Jurisdiction | Schedule/Classification | Notes |
|---|---|---|
| **United States** | DEA Schedule IV (Controlled Substances Act) | Prescription required; 5 refills per 6 months |
| **United Kingdom** | Class C (Misuse of Drugs Act) | Not available on NHS; private prescription only |
| **Canada** | Schedule IV (Controlled Drugs and Substances Act) | Prescription required; unauthorized possession/trafficking criminal offence |
| **Australia** | Schedule 8 (Therapeutic Goods Administration) | Reclassified Feb 2014; not recommended for panic disorder |
| **Germany** | Anlage III (up to 1 mg normal prescription; >1 mg narcotic prescription form required) | |
| **Sweden** | List IV (Narcotics Drugs Act 1968) | |
| **Netherlands** | List 2 (Opium Law) | Available by prescription |
| **UN** | Schedule IV (Convention on Psychotropic Substances) | |

*Sources: Ref 34 (historical/Wikipedia), Ref 43 (Health Canada), Preuss et al. [Ref from brief]*

---

## Clinical Trials

**Completed trials relevant to alprazolam:**

1. **NCT00477451** — "Staccato Alprazolam in Panic Attack" — Phase 2 — Completed — Alexza Pharmaceuticals. Inhaled aerosol (Staccato delivery) for treatment of induced panic attack. *No published PubMed results found for this trial's efficacy data* [FLAG]

2. **NCT00266409** — Phase 4 — Completed — UCB Pharma. Niravam (orally disintegrating alprazolam XR) + SSRI/SNRI vs. SSRI/SNRI alone for GAD/panic disorder. Time to response comparison.

3. **NCT00803400** — Phase 4 — Completed — University of Buenos Aires. Aerobic exercise added to alprazolam for panic disorder treatment.

4. **NCT00004373** — Phase 2 — Completed — NIDA. Double-blind, placebo-controlled study of reinforcing effects of alprazolam in anxiety patients.

5. **NCT00198094** — Phase 4 — Completed — Indiana University School of Medicine. Sertraline + early alprazolam XR vs. sertraline alone in panic disorder.

6. **NCT00634790, NCT00635531, NCT00635076** — Phase 4 — **Terminated** — Pfizer/Upjohn (now Viatris). Safety studies of alprazolam XR in adolescents with panic disorder — terminated, suggesting safety concerns or insufficient recruitment in pediatric population.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. *(This section is left empty per instructions.)*

---

## Gaps & Flags

### Safety-Critical Values Not Confirmed by Primary Sources

1. **⚠️ FLAG — LD50 data absent:** No published LD50 data for alprazolam found in PubChem, INCHEM, or any PubMed-accessible source. The INCHEM monograph does not provide this value. Cannot confirm or propose LD50.

2. **⚠️ FLAG — Kava interaction severity:** The brief lists kava as "caution" interaction. No published alprazolam+kava pharmacodynamic or pharmacokinetic studies were found. The "caution" designation appears to rest on class-level GABAergic additive effects and potential weak CYP3A4 inhibition by kavalactones. This cannot be confirmed from primary literature.

3. **⚠️ FLAG — Gabapentin interaction severity:** The brief lists gabapentin as "caution." No alprazolam+gabapentin-specific interaction data found in PubMed. Risk is based on class-level additive CNS depression logic (both compounds reduce CNS excitability). Emerging literature on gabapentinoid+BZD combinations suggests risk exists but no alprazolam-specific study found.

4. **⚠️ FLAG — Inhaled route PK data:** The brief lists "inhaled" as a known ROA with dose and duration data. Completed clinical trial NCT00477451 evaluated Staccato inhaled alprazolam, but no published pharmacokinetic results for the inhaled route were found in PubMed. Onset and duration data in the brief (onset 5–10 seconds, Tmax 5–10 minutes for inhaled route) cannot be confirmed from published primary sources. These appear to be inferred or from grey literature.

5. **⚠️ FLAG — Pregnancy/neonatal data:** No alprazolam-specific teratogenicity or neonatal withdrawal studies were found in PubMed searches. Contraindication during pregnancy rests on class-level benzodiazepine data (floppy infant syndrome, neonatal withdrawal). Brief lists no contraindications; this should be flagged for addition.

### Contradictions Between Seed Data and Published Sources

6. **⚠️ POTENTIAL CONTRADICTION — Dependence risk:** Verster & Volkerts 2004 (a peer-reviewed comprehensive review) states alprazolam is "unlikely to produce dependency or abuse" at therapeutic doses [Ref 8]. The seed data (and most clinical sources) describe high physical and psychological dependence potential with rapid onset. The Rickels & Schweizer 1998 8-month trial found one-third of patients unable to discontinue [Ref 9]. The Verster claim appears to represent an outlier or to be specifically comparing risk vs. non-prescription populations. This contradiction should be noted by the generation agent — the preponderance of evidence supports high dependence potential.

7. **⚠️ NOTE — "Primary ROA" blank in brief:** Oral is clearly the primary clinical route. Sublingual and inhaled are documented but less common. Brief seed data should have oral as primary ROA.

8. **⚠️ NOTE — Missing PubChem CID confirmed:** CID 2118 confirmed. All missing chemical identity fields now populated.

### Data Absent from Published Literature

9. **No published studies found for:** alprazolam+barbiturate cross-tolerance (class-level inference only); alprazolam-specific teratogenicity; alprazolam stereochemistry (no chiral center, no isomers — structural analysis).

10. **Protein binding specific value:** Greenblatt 1993 notes protein binding is reduced by renal disease but does not give a specific % figure in the accessible abstract. Literature commonly states ~80% for alprazolam based on in vitro studies; this figure should be flagged as needing primary source verification.